<SEC-DOCUMENT>0001493152-24-035018.txt : 20240904
<SEC-HEADER>0001493152-24-035018.hdr.sgml : 20240904
<ACCEPTANCE-DATETIME>20240904184327
ACCESSION NUMBER:		0001493152-24-035018
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20240904
DATE AS OF CHANGE:		20240904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281934
		FILM NUMBER:		241278856

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>forms-1.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ENVB="http://enveric.com/20240830">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_ENVB_enveric.com_20240830 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20240830_20240830 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000004" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20240830.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-08-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-30</xbrli:startDate>
        <xbrli:endDate>2024-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-302024-08-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-30</xbrli:startDate>
        <xbrli:endDate>2024-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on <span id="xdx_903_edei--DocumentCreationDate_c20240830__20240830_zBjGANTGnpmc"><ix:nonNumeric contextRef="AsOf2024-08-30" format="ixt:datemonthdayyearen" id="Fact000009" name="dei:DocumentCreationDate">September 4, 2024</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20240830__20240830_z9ad6LerfYt5"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000010" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_908_edei--EntityRegistrantName_c20240830__20240830_zq6gaYbGJcIi"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000011" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20240830__20240830_z5a65uzgdyta"><ix:nonNumeric contextRef="AsOf2024-08-30" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20240830__20240830_zZItkef3oW8e"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000013" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: -8.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: -8.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
                                            Standard Industrial</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
    Code Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20240830__20240830_zGlNrlmd5EG5"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000014" name="dei:EntityAddressAddressLine1">4851
Tamiami Trail N</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20240830__20240830_znFbXmIeQpkl"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000015" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20240830__20240830_zjb27Oie3d51"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000016" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
<span id="xdx_900_edei--EntityAddressStateOrProvince_c20240830__20240830_zmjv9q59fbj5"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000017" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20240830__20240830_zF99cs5t9w07"><ix:nonNumeric contextRef="AsOf2024-08-30" id="Fact000018" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code, and telephone number, including</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">area
code, of registrant&#8217;s principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--ContactPersonnelName_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zbLECAHVmdxe"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000019" name="dei:ContactPersonnelName">Joseph
Tucker</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zlKUM3fw2U91"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000020" name="dei:EntityAddressAddressLine1">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine2_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zhxWVvsHAFu5"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000021" name="dei:EntityAddressAddressLine2">4851
Tamiami Trail N</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine3_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z9nbxrDkThQ4"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000022" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z1kl63vjR7Rk"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000023" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
<span id="xdx_90A_edei--EntityAddressStateOrProvince_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zv2KTpLJXAGa"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000024" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zVUShPwAwoa7"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000025" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(<span id="xdx_906_edei--CityAreaCode_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z3fgKD5r3zp1"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000026" name="dei:CityAreaCode">239</ix:nonNumeric></span>)
<span id="xdx_902_edei--LocalPhoneNumber_c20240830__20240830__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_z35qUvt5fQEi"><ix:nonNumeric contextRef="From2024-08-302024-08-30_dei_BusinessContactMember" id="Fact000027" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code, and telephone number, including area code, of agent for service)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bradley
J. Wyatt, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adin
J. Tarr, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dickinson
Wright PLLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1850
N. Central Avenue Suite 1400</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Phoenix
AZ 85004</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(734)
623-1905</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate
date of commencement of proposed sale to the public:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time after this registration statement becomes effective, as determined by the selling stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20240830__20240830_zgz9JeQ93H0g"><ix:nonNumeric contextRef="AsOf2024-08-30" format="ixt-sec:entityfilercategoryen" id="Fact000028" name="dei:EntityFilerCategory">Non-accelerated
filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_905_edei--EntitySmallBusiness_c20240830__20240830_zeONCrUzrKs2"><ix:nonNumeric contextRef="AsOf2024-08-30" format="ixt:booleantrue" id="Fact000029" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20240830__20240830_z3F5EVXXa6bl"><ix:nonNumeric contextRef="AsOf2024-08-30" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STATEMENT
PURSUANT TO RULE 429</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant is filing a single prospectus in this registration statement, pursuant to Rule 429 under the Securities Act of 1933. The prospectus
is a combined prospectus relating to (i) 4,900,000 shares of the Common Stock of Enveric Biosciences, Inc., a Delaware corporation (the
&#8220;Company&#8221;) that are being newly registered hereunder and (ii) 1,279,880 shares of Common Stock that are currently registered
under the Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 8,
2023 and amended on December 1, 2023, which was declared effective by the SEC on December 5, 2023 (SEC File No. 333-275380) (the &#8220;Prior
Registration Statement&#8221;) and remain unsold by the Selling Stockholder listed therein. Pursuant to Rule 429 under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement on Form S-1 upon effectiveness will serve as
a post-effective amendment to the Prior Registration Statement. If any securities previously registered under the Prior Registration
Statement are offered and sold before the effective date of this registration statement, the amount of previously registered securities
so sold will not be included in the prospectus hereunder.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration
statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>PRELIMINARY
    PROSPECTUS</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>SUBJECT
    TO COMPLETION</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><b>DATED
    SEPTEMBER 4, 2024</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,900,000
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enveric
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the offer and resale of up to 4,900,000 shares of our common stock, par value $0.01 per share, by Lincoln Park
Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock being offered by the selling stockholder consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">up
    to 4,900,000 shares of common stock that we may elect to issue and sell to Lincoln Park, in our sole discretion from time to time
    after the effective date of this prospectus (the &#8220;Purchase Shares&#8221;), pursuant to a purchase agreement, dated as of November
    3, 2023, that we entered into with Lincoln Park, which we refer to in this prospectus as the &#8220;Purchase Agreement&#8221;, providing
    for up to $9,422,346 of gross proceeds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;The Lincoln Park Transaction&#8221; for descriptions of the Purchase Agreement and &#8220;Selling Stockholder&#8221; for additional
information regarding Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to this prospectus, we may receive gross proceeds of up to $9,422,346 from the sale of our common stock to Lincoln Park under the Purchase
Agreement, from time to time, in our discretion after the date of the registration statement of which this prospectus is a part is declared
effective and after satisfaction of other conditions in the Purchase Agreement. We are not selling any securities under this prospectus
and will not receive any of the proceeds from the sale of the shares by the selling stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2023, we filed a Registration Statement on Form S-1, and an amendment to such Registration Statement on Form S-1 on December
1, 2023, which was declared effective by the SEC on December 5, 2023 (SEC File No. 333-275380) that covered the resale by the selling
stockholder of up to 1,279,880 shares of our common stock, comprised of: (i) up to 1,140,477 shares of our common stock reserved for
sale to Lincoln Park under the Purchase Agreement from time to time after the date of such prospectus, and (ii) 139,403 shares of our
common stock that were issued to Lincoln Park on November 3, 2023 (the &#8220;Commitment Shares&#8221;) in lieu of a cash fee for making
its irrevocable commitment to purchase our common stock under the Purchase Agreement (the &#8220;Prior Registration Statement&#8221;).
As of July 30, 2024, we issued 1,279,880 shares, including the Commitment Shares, registered pursuant to Prior Registration Statement
for a total gross cash proceeds of $577,654.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park may sell the shares of our common stock described in this prospectus in a number of different ways and at varying prices. The price
that Lincoln Park will pay for the shares to be resold pursuant to this prospectus will depend upon the timing of sales and will fluctuate
based on the trading price of our common stock. Lincoln Park is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of
the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price for the Purchase Shares will be based upon formulae set forth in the Purchase Agreement and described in this prospectus
depending on the type of purchase notice we submit to Lincoln Park from time to time. We will pay the expenses incurred in registering
the shares of our common stock, including legal and accounting fees. See &#8220;Plan of Distribution&#8221; on page 18 for more
information about how Lincoln Park may sell the shares of common stock being registered pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;ENVB&#8221;. The last reported
sale price of our common stock on Nasdaq on August 30, 2024 was $0.51 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; under applicable Securities and Exchange Commission rules and will be subject to reduced
public company reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities is highly speculative and involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 6 of this
prospectus and in the documents incorporated by reference into this prospectus for a discussion of information that should be considered
in connection with an investment in our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is [&#9679;], 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">ABOUT THIS PROSPECTUS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">PROSPECTUS SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">THE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">THE LINCOLN PARK TRANSACTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_009">SELLING STOCKHOLDER</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">DESCRIPTION OF SECURITIES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">PLAN OF DISTRIBUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_001"></span>ABOUT
THIS PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, and that includes
exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits
filed with the SEC, together with the additional information described under the headings &#8220;Where You Can Find More Information&#8221;
and &#8220;Incorporation of Certain Information by Reference&#8221; before making your investment decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information provided in this prospectus or any free writing prospectuses or amendments thereto. Neither we, nor
the selling stockholder, have authorized anyone else to provide you with different information. If anyone provides you with different
or inconsistent information, you should not rely on it. You should assume that the information in this prospectus is accurate only as
of the date hereof. Our business, financial condition, results of operations and prospects may have changed since that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we, nor the selling stockholder, are offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer
or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
as to distribution of the prospectus outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_002"></span>PROSPECTUS
SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider
before making your investment decision. Before investing in our securities, you should carefully read this entire prospectus and the
documents incorporated by reference herein, including the &#8220;Risk Factors&#8221; section in this prospectus and under similar captions
in the documents incorporated by reference into this prospectus. If any of the risks materialize, our business, financial condition,
operating results, and prospects could be materially and adversely affected. In that event, the price of our securities could decline,
and you could lose part or all of your investment. Unless we state otherwise or the context otherwise requires, the terms &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; &#8220;our business,&#8221; &#8220;the Company&#8221; and &#8220;Enveric&#8221; refer to and similar
references refer to Enveric Biosciences Inc. and its consolidated subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment
of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary&#8482;, Enveric
has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric&#8217;s
lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing
the first product from the EVM201 Series &#8211; EB-002 (formerly EB-373) &#8211; for the treatment of psychiatric disorders.
Enveric is also advancing its second program, the EVM301 Series &#8211; EB-003 &#8211; expected to offer a first-in-class, new approach
to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing
hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell
company immediately prior to the completion of a &#8220;reverse merger&#8221; transaction on May 26, 2015, whereby Ameri100 Acquisition,
Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc., a Delaware
corporation (the &#8220;2015 Merger&#8221;). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ameri business ceased to be part of the Company on December 30, 2020, pursuant to a spin-off transaction. On December 30, 2020, we completed
a tender offer to purchase all of the outstanding common shares of Jay Pharma Inc., a Canada corporation, for shares of Company common
stock or certain preferred stock, and changed our name to &#8220;Enveric Biosciences, Inc.&#8221; Our principal corporate office is located
at Enveric Biosciences, Inc., 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103, telephone (239) 302-1707. Our internet address
is https://www.enveric.com/. The information contained on, or that can be accessed through, our website is not a part of this prospectus.
Our trademarks and trade names include, but may not be limited to, &#8220;Enveric,&#8221; and the Enveric logo.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, the Company entered into an Amalgamation Agreement (the &#8220;Amalgamation Agreement&#8221;) with 1306432 B.C. Ltd., a
corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (&#8220;HoldCo&#8221;),
1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo
(&#8220;Purchaser&#8221;), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (&#8220;MagicMed&#8221;),
pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed
in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms
and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation, the amalgamated corporation (&#8220;Amalco&#8221;)
will be an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin,
towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities in Australia,
including ongoing interactions with the local Human Research Ethics Committees (&#8220;HREC&#8221;) and the Therapeutic Goods Administration,
Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuroplastogens</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), we have continued to pursue the development
of MagicMed&#8217;s proprietary psychedelic derivatives library, the Psybrary&#8482; which we believe will help us to identify and develop
the right drug candidates needed to address mental health challenges, including anxiety. We synthesize novel versions of classic psychedelics,
such as psilocybin, N,N-Dimethyltryptamine (&#8220;DMT&#8221;), mescaline and MDMA, using a mixture of chemistry and synthetic biology,
resulting in the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million potential variations and hundreds
of synthesized molecules. Within the Psybrary&#8482; we have three different types of molecules, Generation 1 (classic psychedelics),
Generation 2 (pro-drugs), and Generation 3 (new chemical entities).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
screen newly synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (AI) tool. Leveraging
AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. We believe it streamlines pharmaceutical
design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to help determine
ideal drug candidates, tailored to each indication. Each of these molecules that we believe are patentable can then be further screened
to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds of sufficient purity
are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and ultimately clinical
(human) evaluations. We intend to utilize our Psybrary&#8482; and the AI tool to categorize and characterize the Psybrary&#8482; substituents
to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase. The Company has created over 1,000 novel
compounds that are housed in the Psybrary&#8482;. Our primary focus is to develop our lead asset EB-003.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this stage, we have entered into non-binding term sheets with strategic partners that out-license molecules from the Psybrary&#8482;.
Going forward we intend to both develop intellectual property and license intellectual property from pharmaceutical and biotechnology
companies and research institutions which would cover research stage and clinical stage assets to build a pipeline of product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of product candidates and key ongoing development programs are shown in the tables below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    Candidates</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
    Indications</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Partner(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-002</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Second-generation
    psychedelic asset: prodrug of psilocin</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anxiety</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Clinical
    Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    of HREC for FIH study in Australia</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-003</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Third-generation
    psychedelic-inspired new chemical entity</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
    health indication</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Clinical
    Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    Filing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Lincoln Park Equity-Line</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we entered into the Purchase Agreement with Lincoln Park, pursuant to which, subject to the terms and conditions
set forth therein, we may sell to Lincoln Park up to an aggregate of $10.0 million of our common stock from time to time over the term
of the Purchase Agreement. Pursuant to the Purchase Agreement, we issued 139,403 Commitment Shares to Lincoln Park as a fee for making
its irrevocable commitment to purchase our common stock under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we entered into a registration rights agreement with Lincoln Park, which we refer to in this prospectus as the &#8220;Registration
Rights Agreement,&#8221; pursuant to which we filed with the SEC the registration statement that includes this prospectus
to register for resale under the Securities Act, the shares of our common stock that have been or may be issued to Lincoln Park under
the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2023, we filed a Registration Statement on Form S-1, and an amendment to such Registration Statement on Form S-1 on December
1, 2023, which was declared effective by the SEC on December 5, 2023 (SEC File No. 333-275380) that covered the resale by the selling
stockholder of up to 1,279,880 shares of our common stock, comprised of: (i) up to 1,140,477 shares of our common stock reserved for
sale to Lincoln Park under the Purchase Agreement from time to time after the date of such prospectus, and (ii) 139,403 Commitment Shares
issued to Lincoln Park in lieu of a cash fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement
(the &#8220;Prior Registration Statement&#8221;). As of July 30, 2024, we issued 1,279,880 shares, including the Commitment Shares, registered
pursuant to the Prior Registration Statement for a total gross cash proceeds of $577,654.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
sales of common stock by the Company, if any, will be subject to certain limitations set forth in the Purchase Agreement, and may occur
from time to time, at the Company&#8217;s sole discretion, and may continue from the effective date of this Prospectus (the &#8220;Effective
Date&#8221;) through December 6, 2025 (the &#8220;Maturity Date&#8221;). From and after the Effective Date, we may, from time to time
and at our sole discretion until the Maturity Date, on any business day that we select, direct Lincoln Park to purchase up to 25,000
shares of our common stock if the price is not below $0.10, up to 30,000 shares if not below $5.00, and up to 35,000 if the price is
not below $10.00, subject to a maximum commitment of $500,000 per purchase, which we refer to in this prospectus as &#8220;Regular Purchases.&#8221;
The purchase price per share of common stock sold in each such Regular Purchase, if any, will be equal to the lesser of (i) the lowest
sale of the common stock during the Purchase Date or (ii) the average of the three (3) lowest sale prices of the common stock during
the ten (10) business days prior to the Purchase Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to Regular Purchases, provided that we have directed Lincoln Park to purchase the maximum amount of shares that we are then
able to sell to Lincoln Park in a Regular Purchase, we may, in our sole discretion, also direct Lincoln Park to purchase additional shares
of common stock in &#8220;accelerated purchases,&#8221; and &#8220;additional accelerated purchases&#8221; as set forth in the Purchase
Agreement, provided that all shares of common stock subject to all prior Regular Purchases, accelerated purchases and additional accelerated
purchases (as applicable) that we have effected under the Purchase Agreement have been received by Lincoln Park before we deliver notice
to Lincoln Park for the applicable accelerated purchase or additional accelerated purchase in accordance with the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will control the timing and amount of any sales of our common stock to Lincoln Park. The purchase price of the shares of our common stock
that may be sold to Lincoln Park in Regular Purchases, accelerated purchases, and additional accelerated purchases under the Purchase
Agreement will be based on the market price of our common stock immediately preceding the time of sale as computed under the Purchase
Agreement. The purchase price per share will be equitably adjusted as provided in the Purchase Agreement for any reorganization, recapitalization,
non-cash dividend, stock split, or other similar transaction as set forth in the Purchase Agreement. We may at any time in our sole discretion
terminate the Purchase Agreement without fee, penalty or cost upon one business day notice. In the event of bankruptcy proceedings by
or against us, the Purchase Agreement will automatically terminate without action of any party. No termination of the Purchase Agreement
will be effective during the pendency of any Regular Purchase, accelerated purchase or additional accelerated purchase that has not then
fully settled in accordance with the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase
Agreement or Registration Rights Agreement, except the Company is prohibited (with certain specified exceptions set forth in the Purchase
Agreement) from effecting or entering into an agreement to effect an &#8220;equity line of credit&#8221; or other continuous offering
or similar offering in which the Company may issue and sell common stock, from time to time over a certain period of time, at future
determined prices based on the market prices of the common stock at the time of each such issuance and sale. Lincoln Park has represented
to us that at no time prior to the time of execution of the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates
engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation
SHO under the Exchange Act) of our Common Stock or any hedging transaction, which establishes a net short position with respect to our
Common Stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will
not enter into or effect, directly or indirectly, any of the foregoing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 30, 2024, there were 8,919,920 shares of our common stock outstanding. Although the Purchase Agreement provides that
we may sell up to an aggregate of $10.0 million of our common stock to Lincoln Park, we have already sold 1,279,880 shares, under a separate
prospectus as part of the Prior Registration Statement, which included the 139,403 Commitment Shares that we already issued to Lincoln
Park as a fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement. The purpose of this registration
statement on Form S-1 is to register the Purchase Shares for resale by Lincoln Park, pursuant to the terms of the Purchase Agreement
and the Registration Rights Agreement. Depending on the market prices of our common stock at the time we elect to issue and sell shares
of our common stock to Lincoln Park under the Purchase Agreement, we may need to register for resale under the Securities Act additional
shares of our common stock in order to receive aggregate gross proceeds equal to the $10.0 million total commitment available to us under
the Purchase Agreement. If we elect to issue and sell to Lincoln Park under the Purchase Agreement more than the 4,900,000 shares of
our common stock being registered for resale by Lincoln Park under this prospectus, which we have the right, but not the obligation,
to do, we must first register for resale under the Securities Act any such additional shares of our common stock, which could cause additional
substantial dilution to our stockholders. The number of shares of our common stock ultimately offered for resale by Lincoln Park is dependent
upon the number of shares of our common stock we ultimately decide to sell to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of 7,692,308 shares (including
the shares registered under the Prior Registration Statement), which represents the amount approved by our stockholders at the Company&#8217;s
Annual Meeting of Stockholders on November 2, 2023 pursuant to Nasdaq Marketplace Rules 5635(a), (b), and (d), which limitation we refer
to as the Stockholder Approved Exchange Cap, unless we obtain further stockholder approval to issue shares of our common stock in excess
of the Stockholder Approved Exchange Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement prohibits us from directing Lincoln Park to purchase any shares of our common stock if those shares of our common
stock, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result
in Lincoln Park having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of
our common stock, as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and
Rule 13d-3 thereunder, which limitation we refer to as the Beneficial Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances
of our common stock to Lincoln Park under the Purchase Agreement will not affect the rights or privileges of our existing stockholders,
except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance.
Although the number of shares of our common stock that our existing stockholders own will not decrease, the shares of our common stock
owned by our existing stockholders will represent a smaller percentage of our total outstanding shares of our common stock after any
such issuance of shares of our common stock to Lincoln Park under the Purchase Agreement. There are substantial risks to our stockholders
as a result of the sale and issuance of common stock to Lincoln Park under the Purchase Agreement. See &#8220;Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary executive offices are located at 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 and our telephone number is (239) 302-1707.
Our website address is <i>www.enveric.com</i>. The information contained on, or that can be accessed through, our website is not part
of this prospectus and should not be considered as part of this prospectus or in deciding whether to purchase our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psybrary,
PsyAI and our logo are some of our trademarks used in this prospectus. This prospectus also includes trademarks, tradenames and service
marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus
may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert,
to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and tradenames.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined in the Exchange Act, and we will remain a smaller reporting company until the fiscal year
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business
    day of our second fiscal quarter; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    annual revenue is more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock
    held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations,
including, among other things, being required to provide only two years of audited financial statements and not being required to provide
selected financial data, supplemental financial information or risk factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as a non-accelerated filer, we will not be required to provide an auditor attestation of management&#8217;s assessment of internal control
over financial reporting, which is generally required for SEC reporting companies under Sarbanes-Oxley Act Section 404(b), and, in contrast
to other reporting companies, we&#8217;ll have more time to file our annual and periodic reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_003"></span>THE
OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    of our common stock offered by the selling stockholder</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
                                            to 4,900,000 shares of common stock consisting of:</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    up to 4,900,000 shares of our common stock that we may issue and sell to Lincoln Park from time to time under the Purchase Agreement
    from and after the effective date of this prospectus until the Maturity Date.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling
    stockholder</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
    Park Capital Fund, LLC. See &#8220;Selling Stockholder&#8221; on page 14 of this prospectus.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    stock outstanding prior to this offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,919,920
                                            shares.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    stock outstanding immediately after this offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,819,920
    shares, assuming the sale of 4,900,000 shares. The actual number of shares issued will vary depending on the sales prices in this
    offering.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of Proceeds</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will receive no proceeds from the sale of shares of our common stock by Lincoln Park pursuant to this prospectus. We may receive
    up to an additional $9,422,346 aggregate gross proceeds under the Purchase Agreement from any sales of shares of our common stock
    we make to Lincoln Park pursuant to the Purchase Agreement, assuming that we sell the full amount of our common stock that we have
    the right, but not the obligation to sell to Lincoln Park under the Purchase Agreement. Any proceeds that we receive from sales of
    shares of our common stock to Lincoln Park under the Purchase Agreement will be used for general corporate purposes. See &#8220;Use
    of Proceeds.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
    Capital Markets Symbols</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on Nasdaq under the symbol &#8220;ENVB&#8221;.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in our securities involves a high degree of risk and could result in a loss of your entire investment. See &#8220;Risk Factors&#8221;
    beginning on page 6, and the other information included and incorporated by reference in this prospectus for a discussion of the
    factors you should consider carefully before deciding to invest in our securities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of our common stock to be outstanding immediately after this offering is based on 8,919,920 shares of our common stock
outstanding as of August 30, 2024 and excludes, as of such date, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,082
    shares of our Common Stock issuable upon exercise of outstanding options granted under our equity incentive plans at a weighted average
    exercise price of $62.77 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,257
    shares of our Common Stock available for issuance or future grant pursuant to our equity incentive plan;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">372,142
    shares of our Common Stock issuable upon vesting of restricted stock units granted, inclusive of 16,026 shares previously vested
    and unissued, under our equity incentive plans; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">844,607
    shares of our Common Stock issuable upon exercise of outstanding warrants at a weighted average exercise price of $35.78 per
    share and 70,000 shares of our Common Stock issuable upon exercise of outstanding investment options at a weighted average exercise
    price of $10.00 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_004"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our securities involves a high degree of risk. Before deciding whether to purchase our securities, including the shares
of common stock offered by this prospectus, you should carefully consider the risks and uncertainties described under &#8220;Risk Factors&#8221;
in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, any subsequent Quarterly Report on Form 10-Q and our other
filings with the SEC, all of which are incorporated by reference herein. If any of these risks actually occur, our business, financial
condition and results of operations could be materially and adversely affected and we may not be able to achieve our goals, the value
of our securities could decline and you could lose some or all of your investment. Additional risks not presently known to us or that
we currently believe are immaterial may also significantly impair our business operations. If any of these risks occur, our business,
results of operations or financial condition and prospects could be harmed. In that event, the market price of our common stock, and
you could lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
is not possible to predict the actual number of shares of common stock we may sell to Lincoln Park under the Purchase Agreement, or the
actual gross proceeds resulting from those sales.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our common stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and
prior to any such sales, the number of shares of common stock that we will sell to Lincoln Park under the Purchase Agreement, the purchase
price per share that Lincoln Park will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds
that we will receive from those purchases by Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park may sell the shares of our common stock described in this prospectus in a number of different ways and at varying prices. The number
of shares of our common stock ultimately offered for sale by Lincoln Park is dependent upon the number of shares of common stock, if
any, we ultimately sell to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
terms of the Purchase Agreement limit the amount of shares of common stock we may issue to Lincoln Park, which may limit our ability
to utilize the arrangement to enhance our cash resources.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement includes restrictions on our ability to sell shares of common stock to Lincoln Park, including, subject to specified
limitations, if a sale would cause Lincoln Park and its affiliates to exceed the Beneficial Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we cannot guarantee that we will be able to sell all the Purchase Shares in this offering. If we cannot sell the full amount of the shares
of common stock that Lincoln Park has committed to purchase because of these limitations, we may be required to utilize more costly and
time-consuming means of accessing the capital markets, which could materially adversely affect our liquidity and cash position. If we
choose to sell more shares of common stock than are offered under this prospectus, we must first register for resale under the Securities
Act such additional shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investors
who buy shares at different times will likely pay different prices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold
to Lincoln Park. If and when we do elect to sell shares of our common stock to Lincoln Park pursuant to the Purchase Agreement, after
Lincoln Park has acquired such shares, Lincoln Park may resell all, some or none of such shares at any time or from time to time in its
discretion and at different prices. As a result, investors who purchase shares from Lincoln Park in this offering at different times
will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution
and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from
Lincoln Park in this offering as a result of future sales made by us to Lincoln Park at prices lower than the prices such investors paid
for their shares in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock by Lincoln Park that
it acquires pursuant to the Purchase Agreement, or the perception that such sales may occur, could cause the price of our common stock
to decrease.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 33pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase
up to $10.0 million of our common stock. Upon the execution of the Purchase Agreement, we issued 139,403 Commitment Shares to Lincoln
Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement. The shares of our common stock
that may be issued under the Purchase Agreement may be sold by us to Lincoln Park at our sole discretion from time to time after Effective
Date of this prospectus through December 6, 2025, the Maturity Date. The purchase price for the shares that we may sell to Lincoln
Park under the Purchase Agreement will fluctuate based on the trading price of our common stock. Depending on market liquidity at the
time, sales of such shares may cause the trading price of our common stock to decrease. We generally have the right to control the timing
and amount of any future sales of our shares to Lincoln Park. Additional sales of our common stock, if any, to Lincoln Park will depend
upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of
the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do
sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at
any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests
of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or
the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time
and at a price that we might otherwise wish to effect sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Lincoln Park, you may
not agree with how we use the proceeds and the proceeds may not be invested successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion as to the use of the net proceeds from our sale of shares of common stock to Lincoln Park, and
we could use them for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying
on the judgment of our management with regard to the use of those net proceeds, and you will not have the opportunity, as part of your
investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest
those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management to use such funds effectively
could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we will not declare cash dividends on our common stock in the foreseeable future, stockholders must rely on appreciation of the value
of our common stock for any return on their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain any future earnings from
the development, operation and expansion of our business and will not declare or pay any cash dividends in the foreseeable future. As
a result, only appreciation of the price of our common stock, if any, will provide a return to investors in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event that we fail to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing
requirements of Nasdaq, our common stock may be delisted, which could affect our market price and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. For continued listing on Nasdaq, we will be required to comply with the continued listing requirements,
including the minimum market capitalization standard, the stockholders&#8217; equity requirement, the corporate governance requirements
and the minimum closing bid price requirement, among other requirements. On May 16, 2024, the Company received a letter from the Listing
Qualifications Department of the Nasdaq Stock Market stating that because the closing bid price for the Company&#8217;s common stock
listed on Nasdaq was below $1.00 for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for
continued listing on the Nasdaq Capital Market (the &#8220;Minimum Bid Price Requirement&#8221;). The Company has a period of 180 calendar
days from May 16, 2024, or until November 12, 2024, to regain compliance with the Minimum Bid Price Requirement. If at any time before
November 12, 2024, the bid price of the Company&#8217;s common stock closes at or above $1.00 per share for a minimum of 10 consecutive
business days, Nasdaq will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 31.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we fail to regain compliance with the Minimum Bid Price Requirement or satisfy any of the listing requirements of Nasdaq,
our common stock may be delisted. We will have an opportunity to appeal the determination to a Hearings Panel, but we cannot guarantee
that such appeal will be successful. If we are unable to list on Nasdaq, we would likely be more difficult to trade in or obtain accurate
quotations as to the market price of our common stock. If our common stock is delisted from trading on Nasdaq, and we are not able to
list our common stock on another exchange or to have it quoted on Nasdaq, our securities could be quoted on the OTC Bulletin Board or
on the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage for our Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3 or obtain
    additional financing in the future).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_005"></span>CAUTIONARY
NOTE REGARDING FORWARD LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for historical information, this prospectus and any documents we incorporate by reference contain forward-looking statements within the
meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Such forward-looking statements include, among others,
those statements including the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221;
&#8220;estimates,&#8221; &#8220;plans,&#8221; and words of similar import. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially
different from any future results, performance or achievements expressed or implied by such forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and
other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by
the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements
of historical fact or as guarantees or assurances of future performance. You should understand that many important factors, in addition
to those discussed in this prospectus, the accompanying prospectus and any documents we incorporate by reference, could cause our results
to differ materially from those expressed in the forward-looking statements. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include changes in local, regional, national, or global political, economic,
business, competitive, market (supply and demand) and regulatory conditions and the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependence on the success of our prospective product candidates, which are in early stages of development and may not reach a particular
    stage in development, receive regulatory approval or be successfully commercialized;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    difficulties that may delay, suspend, or scale back our efforts to advance additional early research programs through preclinical
    development and investigational new drug application filings and into clinical development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that the cost savings, synergies and growth from our combination with MagicMed Industries Inc. and the successful use of the
    rights and technologies acquired in the combination may not be fully realized or may take longer to realize than expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limited study on the effects of medical cannabinoids and psychedelics, and the chance that future clinical research studies may lead
    to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy,
    dosing, and social acceptance of cannabinoids or psychedelics;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expensive, time-consuming, and uncertain nature of clinical trials, which are susceptible to change, delays, termination, and differing
    interpretations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to establish that potential products are efficacious or safe in preclinical or clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    fact that our current and future preclinical and clinical studies may be conducted outside the United States, and the United States
    Food and Drug Administration may not accept data from such studies to support any new drug applications we may submit after completing
    the applicable developmental and regulatory prerequisites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively and efficiently build, maintain and legally protect our molecular derivatives library so that it can be an
    essential building block from which those in the biotech industry can develop new patented products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish or maintain collaborations on the development of therapeutic candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain appropriate or necessary governmental approvals to market potential products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to manufacture product candidates on a commercial scale or in collaborations with third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    significant and increasing liquidity needs and potential requirements for additional funding;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain future funding for developing products and working capital and to obtain such funding on commercially reasonable
    terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislative
    changes related to and affecting the healthcare system, including, without limitation, changes and proposed changes to the Patient
    Protection and Affordable Care Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    intense competition we face, often from companies with greater resources and experience than us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain key executives and scientists;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to secure and enforce legal rights related to our products, including intellectual property rights and patent protection;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political,
    economic, and military instability in Israel which may impede our development programs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
sections of this prospectus and any documents we incorporate by reference describe additional risk factors that could adversely impact
our business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from
time to time, and it is not possible for our management to predict all risk factors and uncertainties, nor are we able to assess the
impact of all of these risk factors on our business or the extent to which any risk factor, or combination of risk factors, may cause
actual results to differ materially from those contained in any forward-looking statements. These risks and others described under the
section &#8220;Risk Factors&#8221; in this prospectus and any documents we incorporate by reference are not exhaustive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
these uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein
to reflect future events or developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_006"></span>THE
LINCOLN PARK TRANSACTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus covers the resale by the selling stockholder of up to 4,900,000 shares of our common stock, all of which we have reserved
for sale to Lincoln Park under the Purchase Agreement from time to time after the date of this prospectus, if and when we determine to
sell additional shares of our common stock to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we entered into the Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has agreed to purchase from
us up to an aggregate of $10.0 million of our common stock (subject to certain limitations) from time to time over the term of the Purchase
Agreement. Pursuant to the Purchase Agreement we issued 139,403 Commitment Shares to Lincoln Park as a fee for making its irrevocable
commitment to purchase our common stock under the Purchase Agreement. Capitalized terms used herein that are not otherwise defined have
the meaning assigned in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we entered into the Registration Rights Agreement, pursuant to which we filed with the SEC the registration statement
that includes this prospectus to register for resale under the Securities Act, the shares of our common stock that have been or may be
issued to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 8, 2023, we filed a Registration Statement on Form S-1, and an amendment to such Registration Statement on Form S-1 on December
1, 2023, which was declared effective by the SEC on December 5, 2023 (SEC File No. 333-275380) that covered the resale by the selling
stockholder of up to 1,279,880 shares of our common stock, comprised of: (i) up to 1,140,477 shares of our common stock reserved for
sale to Lincoln Park under the Purchase Agreement from time to time after the date of such prospectus, and (ii) 139,403 Commitment Shares
issued to Lincoln Park in lieu of a cash fee for making its irrevocable commitment to purchase our common stock under the Purchase Agreement
(the &#8220;Prior Registration Statement&#8221;). As of July 30, 2024, we issued 1,279,880 shares, including the Commitment Shares, registered
pursuant to Prior Registration Statement for a total gross cash proceeds of $577,654.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have the right to commence any further sales of our common stock to Lincoln Park under the Purchase Agreement until all of the
conditions set forth in the Purchase Agreement have been satisfied, including that the SEC has declared effective the registration statement
that includes this prospectus registering the shares of our common stock that have been and may be issued and sold to Lincoln Park under
the Purchase Agreement, which we refer to in this prospectus as the Effective Date. From and after the Effective Date, we may, from time
to time and at our sole discretion until the Maturity Date on any business day that we select, direct Lincoln Park to purchase up to
25,000 shares of our common stock, which amount may be increased depending on the market price of our common stock at the time of sale,
subject to a maximum commitment of $500,000 per purchase, which we refer to in this prospectus as &#8220;Regular Purchases.&#8221; In
addition, at our discretion, Lincoln Park has committed to purchase other &#8220;accelerated amounts&#8221; and/or &#8220;additional
accelerated amounts&#8221; under certain circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will control the timing and amount of any sales of our common stock to Lincoln Park. The purchase price of the shares of our common stock
that may be sold to Lincoln Park in Regular Purchases, accelerated purchases, and additional accelerated purchases under the Purchase
Agreement will be based on the market price of our common stock immediately preceding the time of sale as computed under the Purchase
Agreement. The purchase price per share will be equitably adjusted as provided in the Purchase Agreement for any reorganization, recapitalization,
non-cash dividend, stock split, or other similar transaction as set forth in the Purchase Agreement. We may at any time in our sole discretion
terminate the Purchase Agreement without fee, penalty or cost upon one business day notice. Actual sales of shares of common stock by
the Company to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time
to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the
appropriate sources of funding for the Company and its operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of August 30, 2024, there were 8,919,920 shares of our common stock outstanding. Although the Purchase Agreement provides that
we may sell up to an aggregate of $10.0 million of our common stock to Lincoln Park, 1,279,880 shares (which includes the 139,403 Commitment
Shares that we already issued to Lincoln Park as a fee for making its irrevocable commitment to purchase our common stock under the Purchase
Agreement) of our common stock have already been sold for gross cash proceeds of $577,654 pursuant to the Prior Registration Statement,
and 4,900,000 shares are being registered for resale under this prospectus. Depending on the market prices of our common stock at the
time we elect to issue and sell shares of our common stock to Lincoln Park under the Purchase Agreement, we may need to register for
resale under the Securities Act additional shares of our common stock in order to receive aggregate gross proceeds equal to the $9,422,346
remaining of the commitment available to us under the Purchase Agreement. If we elect to issue and sell to Lincoln Park under the Purchase
Agreement more than the 4,900,000 shares of our common stock being registered for resale by Lincoln Park under this prospectus, which
we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares
of our common stock, which could cause additional substantial dilution to our stockholders. The number of shares of our common stock
ultimately offered for resale by Lincoln Park is dependent upon the number of shares of our common stock we ultimately decide to sell
to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of 7,692,308 shares (including
shares registered under the Prior Registration Statement), which represents the amount approved by our stockholders at the Company&#8217;s
Annual Meeting of Stockholders on November 2, 2023, pursuant to Nasdaq Marketplace Rules 5635(a), (b), and (d), which limitation we refer
to as the Stockholder Approved Exchange Cap, unless we obtain further stockholder approval to issue shares of our common stock in excess
of the Stockholder Approved Exchange Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement prohibits us from directing Lincoln Park to purchase any shares of our common stock if those shares of our common
stock, when aggregated with all other shares of our common stock then beneficially owned by Lincoln Park and its affiliates, would result
in Lincoln Park having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of
our common stock, as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and
Rule 13d-3 thereunder, which limitation we refer to as the Beneficial Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuances
of our common stock to Lincoln Park under the Purchase Agreement will not affect the rights or privileges of our existing stockholders,
except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance.
Although the number of shares of our common stock that our existing stockholders own will not decrease, the shares of our common stock
owned by our existing stockholders will represent a smaller percentage of our total outstanding shares of our common stock after any
such issuance of shares of our common stock to Lincoln Park under the Purchase Agreement. There are substantial risks to our stockholders
as a result of the sale and issuance of common stock to Lincoln Park under the Purchase Agreement. See &#8220;Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchase
of Shares of our Common Stock Under the Purchase Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Regular
Purchases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
and after the Effective Date, on any business day selected by the Company (and provided all shares of common stock subject to all prior
Regular Purchases have been properly delivered to Lincoln Park in accordance with the Purchase Agreement), the Company may, by written
notice delivered by us to Lincoln Park, direct Lincoln Park to purchase up to 25,000 shares of our common stock on such business day
in a Regular Purchase, provided that the closing sale price per share is not below $0.10, however, that the maximum number of shares
we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 30,000 shares of our common stock, provided that the
closing sale price of our common stock is not below $5.00 on the purchase date, and (ii) 35,000 shares of our common stock, provided
that the closing sale price of our common stock is not below $10.00 on the purchase date (such share amount limitation, the &#8220;Regular
Purchase Share Limit&#8221;). In each case, Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $500,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price per share for each such Regular Purchase will be equal to the lower of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lowest sale price for our common stock on the purchase date for such shares of our common stock; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    arithmetic average of the three lowest closing sale prices for our common stock during the 10 consecutive business days ending on
    the business day immediately preceding the purchase date of such shares of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
purchase notice for a Regular Purchase may only be issued after the markets have closed (i.e., after 4:00 pm Eastern time), which ensures
that the purchase price is always known and fixed at the time the purchase notice is issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accelerated
Purchases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to Regular Purchases described above, we may also direct Lincoln Park, on any Purchase Date for a Regular Purchase on which
we have properly submitted a Regular Purchase notice directing Lincoln Park to purchase the maximum number of shares of our common stock
that we are then permitted to include in a single Regular Purchase notice (and provided all shares of common stock subject to all prior
Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases effected prior to such Purchase Date have been properly
delivered to Lincoln Park in accordance with the Purchase Agreement), to purchase an additional amount of our common stock, which we
refer to as an Accelerated Purchase, on the next business day following such Purchase Date for such corresponding Regular Purchase, which
we refer to as the Accelerated Purchase Date, not to exceed the lesser of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30%
    of the aggregate number of shares of our common stock traded during all or, if certain trading volume or market price thresholds
    specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase Date, the portion of the normal trading hours
    on the applicable Accelerated Purchase Date prior to such time that any one of such thresholds is crossed, which period of time on
    the applicable Accelerated Purchase Date we refer to as the Accelerated Purchase Measurement Period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300%
    of the number of Purchase Shares directed by the Company to be purchased by Lincoln Park pursuant to the Regular Purchase Notice
    for the corresponding Regular Purchase to the Accelerated Purchase effected on such same Accelerated Purchase Date (subject to the
    Purchase Share limitations, an amount equal to (A) the Accelerated Purchase Share Percentage multiplied by (B) the total number (or
    volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Accelerated Purchase date beginning
    at the Accelerated Purchase Commencement Time for such Accelerated Purchase and ending at the Accelerated Purchase Termination Time
    for such Accelerated Purchase.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price per share for the shares subject to an Accelerated Purchase will be equal to 94% of the lower of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volume weighted average price of our common stock during the Accelerated Purchase Measurement Period on the applicable Accelerated
    Purchase Date; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    closing sale price of our common stock on the applicable Accelerated Purchase Date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Additional
Accelerated Purchases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also direct Lincoln Park, by written notice delivered to Lincoln Park, not later than 1:00 p.m., Eastern Time, on the same Accelerated
Purchase Date on which an Accelerated Purchase Measurement Period for an Accelerated Purchase has ended prior to such time (and provided
all shares of common stock subject to all prior Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, including
those prior Accelerated Purchases and Additional Accelerated Purchases effected on the same Accelerated Purchase Date as the applicable
Additional Accelerated Purchase have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such
time), to purchase an additional amount of our common stock on such same Accelerated Purchase Date, which we refer to as an Additional
Accelerated Purchase, of up to the lesser of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30%
    of the aggregate number of shares of our common stock traded during the portion of the normal trading hours on the applicable Accelerated
    Purchase Date determined in accordance with the Purchase Agreement, which period of time on the applicable Accelerated Purchase Date
    we refer to as the Additional Accelerated Purchase Measurement Period; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">300%
    of the number of Purchase Shares directed by the Company to be purchased by Lincoln Park pursuant to the Regular Purchase Notice
    for the corresponding Regular Purchase to the Additional Accelerated Purchase effected on such same Additional Accelerated Purchase
    Date (subject to the Purchase Share limitations, an amount equal to (A) the Additional Accelerated Purchase Share Percentage multiplied
    by (B) the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable
    Additional Accelerated Purchase date beginning at the Additional Accelerated Purchase Commencement Time for such Additional Accelerated
    Purchase and ending at the Additional Accelerated Purchase Termination Time for such Additional Accelerated Purchase.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purchase price per share for the shares subject to an Additional Accelerated Purchase will be equal to 94% of the lower of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volume weighted average price of our common stock during the applicable Additional Accelerated Purchase Measurement Period for such
    Additional Accelerated Purchase; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    closing sale price of our common stock on the applicable same Accelerated Purchase Date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in our sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park prior to 1:00 p.m., Eastern Time,
on a single Accelerated Purchase Date, again provided all shares of common stock subject to all prior Regular Purchases, Accelerated
Purchases and Additional Accelerated Purchases, including those prior Accelerated Purchases and Additional Accelerated Purchases effected
on the same Accelerated Purchase Date as the applicable Additional Accelerated Purchase have been properly delivered to Lincoln Park
in accordance with the Purchase Agreement prior to such time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be equitably
adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring
during the business days used to compute the purchase price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described above, there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the
timing and amount of any sales of our common stock to Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Minimum
Share Price</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.05pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Purchase Agreement, we and Lincoln Park may not effect any sales of shares of our common stock under the Purchase Agreement on any
purchase date that the closing sale price of our common stock is less than the floor price of $0.10 per share of common stock, which
will be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.05pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Events
of Default</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
events of default under the Purchase Agreement include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of the registration statement of which this prospectus forms a part lapses for any reason (including, without limitation,
    the issuance of a stop order), or any required prospectus are unavailable for the resale by Lincoln Park of our common stock offered
    hereby, and such lapse or unavailability continues for a period of 10 consecutive business days or for more than an aggregate of
    30 business days in any 365-day period;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    by our principal market of our common stock from trading for a period of one business day;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    delisting of our common stock from Nasdaq, our principal market, provided our common stock is not immediately thereafter trading
    on the New York Stock Exchange, Nasdaq, the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE American, the NYSE Arca,
    or the OTCQX Best Market or the OTCQB Venture Market operated by OTC Markets Group Inc. (or any nationally recognized successor thereto);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of our transfer agent to issue to Lincoln Park shares of our common stock within two business days after the applicable date
    on which Lincoln Park is entitled to receive such shares of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    breach of the representations or warranties or covenants contained in the Purchase Agreement or Registration Rights Agreement that
    has or could have a material adverse effect on us and, in the case of a breach of a covenant that is reasonably curable, that is
    not cured within five business days;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by or against us; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    at any time we are not eligible to transfer our common stock electronically.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to any other rights and remedies under applicable law and the Purchase Agreement, so long as (i) an Event of Default has occurred
and is continuing, or if any event that, after notice and/or lapse of time, would reasonably be expected to become an Event of Default,
has occurred and is continuing or (ii) if at any time after the Effective Date, the Stockholder Approved Exchange Cap is reached (to
the extent the Stockholder Approved Exchange Cap is applicable pursuant to Section 2(d) hereof), the Company shall not deliver to Lincoln
Park any Regular Purchase Notice, Accelerated Purchase Notice or Additional Accelerated Purchase Notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Termination Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have the unconditional right, at any time, for any reason and without any payment or liability to us, to terminate the Purchase Agreement
upon one business day&#8217;s prior written notice to Lincoln Park. In the event of any voluntary or involuntary bankruptcy proceedings
by or against the Company, the Purchase Agreement would automatically terminate without any action of the Company or Lincoln Park. No
termination of the Purchase Agreement will be effective during the pendency of any Regular Purchase, Accelerated Purchase or Additional
Accelerated Purchase that has not then fully settled in accordance with the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No
Short-Selling or Hedging by Lincoln Park</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park has represented to us that at no time prior to the time of execution of the Purchase Agreement has Lincoln Park or its agents, representatives
or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule
200 of Regulation SHO under the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position
with respect to our Common Stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives
or affiliates will not enter into or effect, directly or indirectly, any of the foregoing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prohibitions
on Certain Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase
Agreement or Registration Rights Agreement, except the Company is prohibited (with certain specified exceptions set forth in the Purchase
Agreement) from effecting or entering into an agreement to effect an &#8220;equity line of credit&#8221; or other continuous offering
or similar offering in which the Company may issue and sell common stock, from time to time over a certain period of time, at future
determined prices based on the market prices of the common stock at the time of each such issuance and sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effect
of Performance of the Purchase Agreement on Our Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the shares of our common stock being registered for resale hereunder, which have been or may be issued or sold by us to Lincoln Park
under the Purchase Agreement are expected to be freely tradable. It is anticipated that shares registered in this offering will be sold
from time to time over a period commencing on the Effective Date through the Maturity Date. From and after the Effective Date, we may,
from time to time and at our sole discretion until the Maturity Date, The sale by Lincoln Park of a significant amount of shares of our
common stock registered in this offering at any given time could cause the market price of our common stock to decline and to be highly
volatile. Sales of our common stock to Lincoln Park, if any, will depend upon market conditions and other factors to be determined by
us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available
for us to sell pursuant to the Purchase Agreement. If and when we do sell additional shares of our common stock to Lincoln Park, after
Lincoln Park has acquired the shares of our common stock, Lincoln Park may resell all, some or none of those shares of our common stock
at any time or from time to time in its discretion. Therefore, sales to Lincoln Park by us under the Purchase Agreement may result in
substantial dilution to the interests of other holders of our common stock. In addition, if we sell a substantial number of shares of
our common stock to Lincoln Park under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares
of our common stock or the mere existence of our arrangement with Lincoln Park may make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control
the timing and amount of any additional sales of our common stock to Lincoln Park and the Purchase Agreement may be terminated by us
at any time at our discretion without any cost to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Purchase Agreement, from and after Effective Date, we have the right, but not the obligation, from time to time to
direct Lincoln Park to purchase up to $9,422,346 of our common stock. Depending on the price per share at which we sell our common stock
to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our
common stock than are being offered under this prospectus in order to receive aggregate gross proceeds equal to the remaining of the
$9,422,346 total commitment available to us under the Purchase Agreement. If we choose to do so, we must first register for resale under
the Securities Act such additional shares of our common stock, which could cause additional substantial dilution to our stockholders.
The number of shares of our common stock ultimately offered for resale by Lincoln Park under this prospectus is dependent upon the number
of shares of our common stock we direct Lincoln Park to purchase under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the amount of gross proceeds we would receive from Lincoln Park from our sale of common stock to Lincoln Park
under the Purchase Agreement at varying purchase prices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid">Assumed Average Purchase Price Per Share</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Registered Shares of our Common Stock to be Issued if Full Purchase(1)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Percentage of Outstanding Shares of our Common Stock After Giving Effect to the Issuance to Lincoln Park(2)</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Gross Proceeds from the Sale of Shares of our Common Stock to Lincoln Park Under the Purchase Agreement(1)</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 22%; text-align: right">0.30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 22%; text-align: right">4,900,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 21%; text-align: right">35.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 21%; text-align: right">1,470,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right">0.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,960,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">0.51</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,499,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right">0.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,940,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">0.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,430,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">$</td><td style="text-align: right">0.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,920,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    the Purchase Agreement provides that we may sell a remainder of up to $9,422,346 of our common stock to Lincoln Park, we are only
    registering 4,900,000 shares of our common stock for resale under this prospectus, which may or may not cover all the shares of our
    common stock we ultimately sell to Lincoln Park under the Purchase Agreement (excluding the 1,279,880 shares of our common stock
    we have already sold to Lincoln Park, including the Commitment Shares), depending on the purchase price per share.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    denominator is based on 8,919,920 shares of our common stock outstanding as of August 30, 2024, adjusted to include the number
    of shares of our common stock set forth in the adjacent column which we would have sold to Lincoln Park, assuming the purchase price
    in the adjacent column. The numerator is based on the number of shares of our common stock issuable under the Purchase Agreement
    at the corresponding assumed purchase price set forth in the adjacent column, without giving effect to the Beneficial Ownership Cap.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    closing sale price per share of our common stock on August 30, 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_007"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to shares of our common stock that may be offered and sold from time to time by Lincoln Park. We will receive no proceeds
from the sale of shares of common stock by Lincoln Park in this offering. We may receive up to $9,422,346 in gross proceeds under the
Purchase Agreement from any sales we make to Lincoln Park pursuant to the Purchase Agreement after the date of this prospectus. We estimate
that the net proceeds to us from the sale of our common stock to Lincoln Park pursuant to the Purchase Agreement would be up to approximately
$9.38 million over the period beginning on the Effective Date until the Maturity Date, assuming that we sell the full remaining amount
of our common stock that we have the right, but not the obligation, to sell to Lincoln Park under the Purchase Agreement, and after other
estimated fees and expenses. See &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently expect to use the net proceeds, if any, from the sale of Common Stock offered hereby for general corporate purposes, which
may include funding research and development, increasing working capital, reducing indebtedness, acquisitions or investments in businesses,
products or technologies that are complementary to their own, and capital expenditures. The amounts and timing of these expenditures
will depend on a number of factors, such as the timing and progress of our research and development efforts, regulatory actions affecting
our product candidates and our business, technological advances and the competitive environment for our product candidates. As we are
unable to predict the timing or amount of potential issuances of all of the additional shares issuable to the Purchase Agreement, we
cannot specify with certainty all of the particular uses for the net proceeds that we will have from the sale of such additional shares.
Accordingly, our management will have broad discretion in the application of the net proceeds. We may also use a portion of the net proceeds
to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no
present commitments or agreements to do so. We may use the proceeds for purposes that are not contemplated at the time of this offering.
Pending use of the net proceeds as described above, we expect to invest the net proceeds in short- and intermediate-term, interest-bearing
obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. It is
possible that no additional shares will be issued under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ar_009"></span>SELLING
STOCKHOLDER</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that have been and
may be issued to Lincoln Park pursuant to the Purchase Agreement. We are filing the registration statement of which this prospectus is
a part pursuant to the provisions of the Registration Rights Agreements, which we entered into with Lincoln Park on November 3, 2023
concurrently with our execution of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to
sales by Lincoln Park of the shares of our common stock that have been and may be issued to Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park, as the selling stockholder, may, from time to time, offer and sell pursuant to this prospectus up to 4,900,000 shares of our common
stock that we have issued or may issue to Lincoln Park. The selling stockholder may sell some, all or none of the shares of common stock.
We do not know how long the selling stockholder will hold the shares of our common stock before selling them, and we currently have no
agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares of common stock. See
&#8220;Plan of Distribution.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the
selling stockholder as of August 30, 2024. The percentages of shares owned before and after the offering are based on
8,919,920 shares of common stock outstanding as of August 30, 2024. The information in the table below with respect to the
selling stockholder has been obtained from the selling stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless
otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power with respect to their
shares of common stock. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for the person
named below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this prospectus, when we refer to the shares of common stock being offered for resale by the selling stockholder through this prospectus,
we are referring to the shares of common stock that have been and may be issued and sold by us to Lincoln Park pursuant to the Purchase
Agreement, unless otherwise indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Name of Selling Stockholder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares of common stock Owned Prior to Offering<sup>(2)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximum Number of Shares of common stock to be Offered Pursuant to this Prospectus<sup>(3)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of Shares of common stock Owned After Offering<sup>(4)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln Park Capital Fund, LLC<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0.07</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,900,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">5,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0.04</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC,
are deemed to be beneficial owners of all of the shares of common stock owned directly by Lincoln Park Capital Fund, LLC. Messrs. Cope
and Scheinfeld have shared voting and investment power over the shares of common stock being offered under the registration statement
filed with the SEC in connection with the transactions contemplated under the Purchase Agreement and the Registration Rights Agreement.
Neither Lincoln Park Capital, LLC nor Lincoln Park Capital Fund, LLC is a licensed broker dealer or an affiliate of a licensed broker
dealer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares of our common stock beneficially
owned prior to the offering all of the 4,900,000 shares of our common stock that we may issue and sell to Lincoln Park pursuant to the
Purchase Agreement from and after Effective Date that are being registered for resale under the registration statement that includes
this prospectus, because the issuance and sale of such shares to Lincoln Park under the Purchase Agreement is solely at our discretion
and is subject to certain conditions, the satisfaction of all of which are outside of Lincoln Park&#8217;s control, including the registration
statement that includes this prospectus becoming and remaining effective under the Securities Act. Furthermore, under the terms of the
Purchase Agreement, issuances and sales of shares of our common stock to Lincoln Park under the Purchase Agreement are subject to certain
limitations on the amounts we may sell to Lincoln Park at any time, including the Beneficial Ownership Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Although the Purchase Agreement provides that we may sell a remainder of up to $9,422,346 of our common stock to Lincoln Park, we are
only registering 4,900,000 shares of our common stock for resale under this prospectus, which represents the shares that we may issue
and sell to Lincoln Park for cash consideration in purchases under the Purchase Agreement from time to time, at our sole discretion, commencing on the Effective Date and ending on the earlier of (i) the Maturity Date, or (ii) the date that all shares offered
by this prospectus have been sold by Lincoln Park. Depending on the price per share at which we sell our common stock to Lincoln Park
pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our common stock
than are offered under this prospectus in order to receive aggregate gross proceeds equal to the full $9,422,346 million available to
us under the Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares.
The number of shares ultimately offered for resale by Lincoln Park is dependent upon the number of shares we sell to Lincoln Park under
the Purchase Agreement. Additionally, in no event may we issue or sell to Lincoln Park under the Purchase Agreement shares of our common
stock in excess of 7,692,308 shares (including shares registered under the Prior Registration Statement), which represents the amount
approved by our stockholders at the Company&#8217;s Annual Meeting of Stockholders on November 2, 2023, pursuant to Nasdaq Marketplace
Rules 5635(a), (b), and (d), which limitation we refer to as the Stockholder Approved Exchange Cap, unless we obtain further stockholder
approval to issue shares of our common stock in excess of the Stockholder Approved Exchange Cap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Assumes the sale of all shares of our common stock registered for resale by the selling stockholder pursuant to the registration statement
that includes this prospectus, although the selling stockholder is under no obligation known to us to sell any shares of common stock
at any particular time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>DESCRIPTION
OF SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following description summarizes the most important terms of our securities. Because it is only a summary, it does not contain all the
information that may be important to you. For a complete description, you should refer to our Amended and Restated Certificate of Incorporation
(&#8220;Certificate of Incorporation&#8221;) and restated bylaws (&#8220;Bylaws&#8221;), each as amended, copies of which are filed as
exhibits to the registration statement of which this prospectus forms a part, which are incorporated by reference herein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
has authorized 120,000,000 shares of capital stock, par value $0.01 per share, of which 100,000,000 are shares of common stock and 20,000,000
are shares of &#8220;blank check&#8221; preferred stock. As of August 30, 2024, there were 8,919,920 shares of Enveric common
stock issued and outstanding, no shares of Series B preferred stock issued and outstanding, 23,082 shares of our Common Stock issuable
upon exercise of outstanding options granted under our equity incentive plans at a weighted average exercise price of $62.77 per share,
844,607 shares of common stock issuable upon exercise of warrants at a weighted average exercise price of $35.78 per share, and
70,000 shares of common stock issuable upon exercise of preferred investment options at a weighted average exercise price of $10.00 per
share, 372,142 shares of our Common Stock issuable upon vesting of restricted stock units granted, inclusive of 16,026 shares previously
vested and unissued. Each of the warrants and the preferred investment options are exercisable for a period of five one and half expiry
periods from 2025 to 2029. The authorized and unissued shares of common stock and the authorized and undesignated shares of preferred
stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the
rules of any stock exchange on which our securities may be listed. Unless approval of our stockholders is so required, our board of directors
does not intend to seek stockholder approval for the issuance and sale of our common stock or preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and have no cumulative
voting rights. Holders of our common stock are entitled to receive ratably dividends as may be declared by our board of directors out
of funds legally available for that purpose, subject to any preferential dividend or other rights of any then outstanding preferred stock.
We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future but intend
to retain our capital resources for reinvestment in our business. Any future disposition of dividends will be at the discretion of our
board of directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements,
and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock do not have preemptive or conversion rights or other subscription rights. Upon liquidation, dissolution or winding-up,
holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences
of any of our outstanding shares of preferred stock. The rights, preferences and privileges of holders of common stock are subject to
and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that is currently outstanding
or that we may designate and issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided by law, our Certificate of Incorporation or Bylaws, in all matters other than the election of directors, the affirmative
vote of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on
the subject matter shall be the act of the stockholders. In addition, except as otherwise provided by law, our Certificate of Incorporation
or Bylaws, directors are elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and
entitled to vote on the election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
B Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our Series B preferred stock are not entitled to voting unless required by applicable law. Each share of Series B preferred stock
will be convertible into one share of common stock (subject to adjustment) at any time at the option of the holders, provided that each
holder would be prohibited from converting Series B preferred stock into shares of common stock if, as a result of such conversion, any
such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding.
This limitation may be waived with respect to a holder upon such holder&#8217;s provision of not less than 61 days&#8217; prior written
notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series B preferred stock are not entitled to receive any dividends, unless and until specifically declared by the board of directors.
However, holders of Series B preferred stock are entitled to receive dividends on shares of Series B preferred stock equal (on an as-if-converted-to-common-stock
basis) to and in the same form as dividends actually paid on shares of common stock when such dividends are specifically declared by
the board of directors. The Company will have no right to require a holder to surrender its Series B preferred stock for redemption.
Shares of Series B preferred stock will not otherwise be entitled to any redemption rights, or mandatory sinking fund or analogous fund
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
entitled to vote, holders of our Series C preferred stock are entitled to 1,000,000 votes per share. Thus, each one-thousandth of a share
of Series C preferred stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series C preferred stock will
vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal
to adopt an amendment to the Company&#8217;s Certificate of Incorporation, to reclassify the outstanding shares of common stock into
a smaller number of shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the
&#8220;Reverse Stock Split&#8221;), (2) any proposal to adopt an amendment to the Certificate of Incorporation to increase the number
of authorized shares of the Corporation&#8217;s common stock (the &#8220;Share Increase Proposal&#8221;) and (3) any proposal to adjourn
any meeting of stockholders called for the purpose of voting on Reverse Stock Split or the Share Increase Proposal (the &#8220;Adjournment
Proposal&#8221;). The Series C preferred stock will not be entitled to vote on any other matter, except to the extent required by applicable
law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C preferred stock, as such, will not be entitled to receive dividends of any kind. The Series C Preferred Stock will
rank senior to the common stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether
voluntarily or involuntarily (a &#8220;Dissolution&#8221;). Upon any Dissolution, each holder of outstanding shares of Series C Preferred
Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference
to any distribution to the holders of common stock, an amount in cash equal to $0.01 per outstanding share of Series C Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, shares of the Series C preferred stock will be redeemed by the Company. The Series C preferred Stock is not convertible
into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series C preferred stock
has no stated maturity and is not subject to any sinking fund. The Series C preferred stock is not subject to any restriction on the
redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transfer Agent and Registrar for our common stock is Equiniti Trust Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects of Certain Provisions of Delaware Law, our Certificate of Incorporation and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delaware
Law</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business
combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
    to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
    which resulted in the stockholder becoming an interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
    owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes
    of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned
    by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject
    to the plan will be tendered in a tender or exchange offer; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special
    meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock
    which is not owned by the interested stockholder.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines a business combination to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    merger or consolidation involving the corporation and the interested stockholder;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the
    interested stockholder; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
    by or through the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In general, Section 203 defines an &#8220;interested stockholder&#8221; as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term &#8220;owner&#8221; is broadly defined to include any person that, individually, with or through that person&#8217;s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject
to Section 203 of the DGCL or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities
exchange or held of record by more than 2,000 stockholders. Our Certificate of Incorporation and Bylaws do not opt out of Section 203.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certificate
of Incorporation and Bylaws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our Certificate of Incorporation and Bylaws, may delay or discourage transactions involving an actual or potential change in our control
or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price
of our common stock. Among other things, Certificate of Incorporation and Bylaws:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    our board of directors to issue up to 20,000,000 shares of preferred stock, without further action by the stockholders, with any
    rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the authorized number of directors may be changed only by a resolution adopted by the entire board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
    not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to
    vote in any election of directors to elect all of the directors standing for election, if they should so choose); and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    advance notice provisions with which a stockholder who wishes to nominate a director or propose other business to be considered at
    a stockholder meeting must comply.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
Effects of Authorized but Unissued Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional
shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions
or payment as a dividend on the capital stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly
to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to
obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of the
Company&#8217;s management. In addition, our board of directors has the discretion to determine designations, rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each
series of preferred stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our Certificate
of Incorporation. The purpose of authorizing our board of directors to issue preferred stock and to determine the rights and preferences
applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred
stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could
have the effect of making it more difficult for a third-party to acquire, or could discourage a third party from acquiring, a majority
of our outstanding voting stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 26.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of our common stock offered by this prospectus are being offered by the selling stockholder, Lincoln Park Capital Fund, LLC. The
shares may be sold or distributed from time to time by the selling stockholder directly to one or more purchasers or through brokers,
dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing
market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of our common stock offered by this prospectus
could be effected in one or more of the following methods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokers&#8217; transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
    involving cross or block trades;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    brokers, dealers, or underwriters who may act solely as agents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;at
    the market&#8221; into an existing market for the shares of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through
    agents;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    privately negotiated transactions; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    combination of the foregoing.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of certain states, if applicable, the shares of our common stock offered by this prospectus
may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares of our common stock offered
by this prospectus may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s
registration or qualification requirement is available and complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park has informed us that it intends to use an unaffiliated broker-dealer to effectuate all sales, if any, of our common stock that it
has acquired and may in the future acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms
then prevailing or at prices related to the then current market price. Each such unaffiliated broker-dealer will be an underwriter within
the meaning of Section 2(a)(11) of the Securities Act. Lincoln Park has informed us that each such broker-dealer will receive commissions
from Lincoln Park that will not exceed customary brokerage commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers,
dealers, underwriters or agents participating in the distribution of the shares of our common stock offered by this prospectus may receive
compensation in the form of commissions, discounts, or concessions from the selling stockholder and/or the purchasers, for whom the broker-dealers
may act as agent. The compensation paid to any such particular broker-dealer may be less than or in excess of customary commissions.
Neither we nor Lincoln Park can presently estimate the amount of compensation that any agent will receive from the selling stockholder
or from any purchasers of shares of our common stock sold by Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
know of no existing arrangements between Lincoln Park or any other stockholder, broker, dealer, underwriter or agent relating to the
sale or distribution of the shares of our common stock offered by this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement that includes
this prospectus to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities
Act, to disclose certain information relating to a particular sale of shares of our common stock offered by this prospectus by the selling
stockholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares of
our common stock by the selling stockholder, any compensation paid by Lincoln Park to any such brokers, dealers, underwriters or agents,
and any other required information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our common stock included
in this prospectus by Lincoln Park. We estimate that the total expenses for the offering will be approximately $40,362. We
have agreed to indemnify Lincoln Park and certain other persons against certain liabilities in connection with the offering of shares
of our common stock offered by this prospectus, including liabilities arising under the Securities Act or, if such indemnity is unavailable,
to contribute amounts required to be paid in respect of such liabilities. Lincoln Park has agreed to indemnify us against liabilities
under the Securities Act that may arise from certain written information furnished to us by Lincoln Park specifically for use in this
prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lincoln
Park has represented to us that at no time prior to the Purchase Agreement has Lincoln Park or its agents, representatives or affiliates
engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation
SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short position with respect to our common
stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter
into or effect, directly or indirectly, any of the foregoing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have advised Lincoln Park that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions,
Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in
the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the
subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order
to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability
of the securities offered by this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on the earlier of (i) the Maturity Date, and (ii) the date that all shares offered by this prospectus have been
sold by Lincoln Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq under the symbol &#8220;ENVB&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the shares of common stock offered by this prospectus will be passed upon for us by Dickinson Wright PLLC, Phoenix, Arizona.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements as of and for the years ended December 31, 2023 and 2022 incorporated by reference in this prospectus
have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their report (the report on the consolidated
financial statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern). Such financial
statements are incorporated by reference in reliance upon the report of such firm given upon their authority as experts in accounting
and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents filed with the SEC are incorporated by reference into this prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Annual Report on Form 10-K for the year ended <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224011210/form10-k.htm" style="-sec-extract: exhibit">December 31, 2023</a>, filed on March 26, 2024 (&#8220;Annual Report&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Quarterly Reports on Form 10-Q for the quarters ended <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224019364/form10-q.htm" style="-sec-extract: exhibit">March 31, 2024</a> and <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224031352/form10-q.htm" style="-sec-extract: exhibit">June 30, 2024</a>, filed with the SEC on May 15, 2024 and August
    12, 2024, respectively;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K, filed on <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224001717/form8-k.htm" style="-sec-extract: exhibit">January 8, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224005561/form8-k.htm" style="-sec-extract: exhibit">February 9, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/form8-k.htm" style="-sec-extract: exhibit">March 11, 2024</a>,  <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224011774/form8-k.htm" style="-sec-extract: exhibit">March 28, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/form8-k.htm" style="-sec-extract: exhibit">May 3, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224020489/form8-k.htm" style="-sec-extract: exhibit">May 17, 2024</a>,
    <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224021096/form8-k.htm" style="-sec-extract: exhibit">May 23, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224021787/form8-k.htm" style="-sec-extract: exhibit">May 29, 2024</a>, <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224027235/form8-k.htm" style="-sec-extract: exhibit">July 15, 2024</a> (other than any portions thereof deemed furnished and not filed); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our common stock contained in our <a href="https://www.sec.gov/Archives/edgar/data/890821/000119380517003427/e617460_8a12bameri.htm" style="-sec-extract: exhibit">Form 8-A12B</a>, filed with the Commission on November 9, 2017 (File No. 001-38286),
    amended and supplemented by the description of our common stock contained in <a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223010431/ex4-1.htm" style="-sec-extract: exhibit">Exhibit 4.1</a> to our Annual Report on Form 10-K for the
    fiscal year ended December 31, 2022, filed with the SEC on March 31, 2023, and any amendment or report filed with the Commission
    for purposes of updating such description.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits
filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made (i) on or after the date of the initial filing of the
registration statement of which this prospectus forms a part and prior to effectiveness of such registration statement, and (ii) on or
after the date of this prospectus but prior to the termination of the offering (i.e., until the earlier of the date on which all of the
securities registered hereunder have been sold or the registration statement of which this prospectus forms a part has been withdrawn).
Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future
filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace
such earlier statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request,
a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including
exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enveric
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4851
Tamiami Trail N,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Suite
200 Naples, FL</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone
(239) 302-1707</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attention:
Corporate Secretary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may also access these documents, free of charge, on the SEC&#8217;s website at <i>www.sec.gov</i> or on our website at <i>https://www.enveric.com/investors/filings/</i>.
The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this
prospectus or any accompanying prospectus supplement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Rule 412 of the Securities Act, any statement contained in a document incorporated by reference herein shall be deemed
modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference herein modifies or supersedes such statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on information contained in, or incorporated by reference into, this prospectus and any prospectus supplement. We have
not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference into
this prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized
or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such an
offer or solicitation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and officers are indemnified to the fullest extent permitted under Delaware law. We also maintain insurance which protects
our officers and directors against any liabilities incurred in connection with their service in such a capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act
and will be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities
we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the
registration statement. You should rely only on the information contained in this prospectus or incorporated by reference into this prospectus.
We have not authorized anyone else to provide you with different information. We are not making an offer of these securities in any jurisdiction
where the offer is not permitted. You should assume that the information contained in this prospectus, or any document incorporated by
reference in this prospectus, is accurate only as of the date of those respective documents, regardless of the time of delivery of this
prospectus or any sale of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Exchange Act and in accordance therewith we file annual, quarterly, and other reports,
proxy statements and other information with the Commission under the Exchange Act. Such reports, proxy statements and other information,
including the Registration Statement, and exhibits and schedules thereto, are available to the public through the Commission&#8217;s
website at www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934,
as amended, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Commission.
The registration statement and the documents referred to under &#8220;<i>Incorporation of Certain Information by Reference</i>&#8221;
are also available on our website enveric.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of
this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,900,000
Shares of common stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_001.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other
than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange
Commission registration fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Securities and Exchange Commission registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">361.62</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accountants&#8217; fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Miscellaneous</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">40,361.62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons who were, are, or are threatened
to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director,
employee or agent of such corporation, or is or was serving at the request of such corporation as an officer, director, employee or agent
of another corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that
such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&#8217;s best
interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal.
A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party to any threatened, pending or completed
action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or
agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another
corporation or enterprise. The indemnity may include expenses (including attorneys&#8217; fees) actually and reasonably incurred by such
person in connection with the defense or settlement of such action or suit provided such person acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the corporation&#8217;s best interests except that no indemnification is permitted
without judicial approval if the officer or director is adjudged to be liable to the corporation. Where an officer or director is successful
on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses
(including attorneys&#8217; fees) actually and reasonably incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, provide for the indemnification of its directors and officers to the fullest extent permitted
under the Delaware General Corporation Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director
of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary
duties as a director, except for liability for any:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transaction
    from which the director derives an improper personal benefit;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">act
    or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unlawful
    payment of dividends or redemption of shares; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of a director&#8217;s duty of loyalty to the corporation or its stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, includes such a provision. Expenses incurred by any officer or director in defending any such action, suit
or proceeding in advance of its final disposition shall be paid by us upon delivery of an undertaking, by or on behalf of such director
or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be
indemnified by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, in connection with a registered direct securities offering of common stock and pre-funded warrants, we sold unregistered
preferred investment options (the &#8220;RD Preferred Investment Options&#8221;) to purchase up to 375,000 shares of common stock (the
&#8220;RD Offering&#8221;). Concurrently with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE
Securities Purchase Agreement&#8221;) with institutional investors for the purchase and sale of 116,000 shares of Common Stock, pre-funded
warrants to purchase up to 509,000 shares of common stock (the &#8220;PIPE Pre-Funded Warrants&#8221;), and preferred investment options
(the &#8220;PIPE Preferred Investment Options&#8221;) to purchase up to 625,000 shares of the common stock in a private placement (the
&#8220;PIPE&#8221;). The RD offering and PIPE closed on July 26, 2022, with aggregate gross proceeds of approximately $8 million. The
aggregate net proceeds from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately
$7.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) acted as the exclusive placement agent for the RD Offering and the PIPE. Upon closing
of the offerings, the Company issued Wainwright preferred investment options to purchase 70,000 shares of Common Stock (the &#8220;Wainwright
Warrants&#8221;). The RD Preferred Investment Options, the PIPE Pre-Funded Warrants, the PIPE Preferred Investment Options, and the Wainwright
Warrants and the shares underlying each of them were issued in reliance on the exemptions from registration provided by Section 4(a)(2)
under the Securities Act and Regulation D promulgated thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, we completed a private placement to Lincoln Park pursuant to which we have the right to sell to Lincoln Park up to
$10.0 million in shares of common stock, subject to certain limitations, from time to time beginning on the Effective Date until the
Maturity Date. As of July 30, 2024, we have issued 1,279,880 shares, including the 139,403 Commitment Shares, to Lincoln Park as consideration
for its commitment to purchase our shares under the Purchase Agreement, for total proceeds of $577,654. In the Purchase Agreement, Lincoln
Park represented to us, among other things, that it was an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a)
of Regulation D under the Securities Act). The securities were and will be sold by us under the Purchase Agreement in reliance upon an
exemption from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000114036120000667/ex2_1.htm" style="-sec-extract: exhibit">Share Purchase Agreement, dated January 10, 2020, by and between AMERI Holdings, Inc. and Ameri100, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 13, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315220015383/ex10-1.htm" style="-sec-extract: exhibit">Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated August 12, 2020, by and among AMERI Holdings, Inc., Jay Pharma Merger Sub, Inc., Jay Pharma Inc., 1236567 B.C. Unlimited Liability Company and Barry Kostiner, as the Ameri representative (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on August 12, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315220023958/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 To Tender Offer Support Agreement and Termination of Amalgamation Agreement, dated December 18, 2020, by and among Ameri, Jay Pharma Merger Sub, Inc., Jay Pharma Inc., 1236567 B.C. Unlimited Liability Company and Barry Kostiner, as the Ameri representative (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 18, 2020)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex2-1.htm" style="-sec-extract: exhibit">Amalgamation Agreement, dated May 24, 2021, by and among Enveric Biosciences, Inc., 1306432 B.C. LTD., 1306436 B.C. LTD., and MagicMed Industries, Inc. (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations of Series B Preferred Stock of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex3-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221029223/ex3-1.htm" style="-sec-extract: exhibit">Amendment to the Amended and Restated Bylaws of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on November 18, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012076/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of the Series C Preferred Stock of the Company, dated May 4, 2022 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on May 4, 2022, File No. 000-26460)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222014217/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment of Certificate of Designation of the Series C Preferred Stock of the Company, dated May 17, 2022 (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Registration Statement on Form 8-A/A, filed with the Securities and Exchange Commission on May 17, 2022, File No. 000 26460)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222019341/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Enveric Biosciences, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 14, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223010431/ex4-1.htm" style="-sec-extract: exhibit">Description of Securities (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex4-1.htm" style="-sec-extract: exhibit">Form of Pre-Funded Warrant (issued in connection with January 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex4-2.htm" style="-sec-extract: exhibit">Form of Warrant (issued in connection with January 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex4-1.htm" style="-sec-extract: exhibit">Form of Warrant (issued in connection with February 2021 Registered Direct Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221007757/ex4-5.htm" style="-sec-extract: exhibit">Form of Series B Warrant (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Annual Report on Form 10-K filed with the Commission on April 1, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/ex4-1.htm" style="-sec-extract: exhibit">Form of MagicMed Warrant Certificate (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222004649/ex4-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant (in connection with February 2022 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 15, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-1.htm" style="-sec-extract: exhibit">Form of RD Pre-Funded Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-2.htm" style="-sec-extract: exhibit">Form of PIPE Pre-Funded Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-3.htm" style="-sec-extract: exhibit">Form of RD Preferred Investment Option (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-4.htm" style="-sec-extract: exhibit">Form of PIPE Preferred Investment Option (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex4-5.htm" style="-sec-extract: exhibit">Form of Wainwright Warrant (in connection with July 2022 Offering) (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223046601/ex4-1.htm" style="-sec-extract: exhibit">Form of Inducement Warrant (in connection with December 2023 Offering) (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 29, 2023)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Dickinson Wright PLLC</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between Kevin Coveney and the Company, effective March 13, 2023 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 28, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-2.htm" style="-sec-extract: exhibit">Certificate of the Designations, Preferences and Rights of Akos Series A Convertible Preferred Stock (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-3.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222012822/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant (entered into in connection with the May 5, 2022 Private Placement) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on May 11, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (in connection with the July 2022 Offerings) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222019341/ex10-1.htm" style="-sec-extract: exhibit">First Amendment to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 14, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-4.htm" style="-sec-extract: exhibit">Form of Warrant Amendment (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-2.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315222020362/ex10-3.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement (in connection with July 2022 Offering) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on July 26, 2022)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex10-5.htm" style="-sec-extract: exhibit">Enveric Biosciences, Inc. 2020 Long-Term Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000336/ex10-6.htm" style="-sec-extract: exhibit">Form of RSU Award Agreement (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated January 11, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated January 11, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221000824/ex10-3.htm" style="-sec-extract: exhibit">Letter Agreement, dated January 11, 2021, by and between the Company and Alpha Capital Anstalt (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on January 12, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated February 9, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221003373/ex10-2.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated February 9, 2021, by and among the Company and the purchasers thereto (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on February 11, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221011946/ex10-6.htm" style="-sec-extract: exhibit">Exclusive License Agreement, between the Company and Diverse Biotech, Inc., dated March 5, 2021 (incorporated by reference to Exhibit 10.6 the Company&#8217;s Quarterly Report on Form 10-Q, filed with the Commission on May 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#o_153" style="-sec-extract: exhibit">Form of Voting and Support Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex B-1 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#o_154" style="-sec-extract: exhibit">Form of Voting Agreement, dated as of May 24, 2021, by and among MagicMed Industries Inc. and certain shareholders of Enveric Biosciences, Inc. named therein (incorporated by reference to Annex B-2 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018886/form424b3.htm#ct_002" style="-sec-extract: exhibit">Form of Lock-Up Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex C-1 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 6, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221018467/forms-4a.htm#ct_001" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Lock-Up/Leak-Out Agreement, dated as of May 24, 2021, by and among Enveric Biosciences, Inc. and certain shareholders of MagicMed Industries Inc. named therein (incorporated by reference to Annex C-2 to the Company&#8217;s Proxy Statement/Prospectus, filed with the Commission on August 3, 2021)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement between Joseph Tucker and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-2.htm" style="-sec-extract: exhibit">Employment Agreement between Peter Facchini and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221012752/ex10-3.htm" style="-sec-extract: exhibit">Employment Agreement between Jillian Hagel and Enveric Biosciences, Inc. (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/ex10-1.htm" style="-sec-extract: exhibit">MagicMed Stock Option Plan, as amended September 10, 2021 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 17, 2021)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223039443/ex10-1.htm" style="-sec-extract: exhibit">Purchase Agreement, dated November 3, 2023, by and among the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the Commission on November 6, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223039443/ex10-2.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated November 3, 2023, by and among the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed with the Commission on November 6, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223046601/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement Warrant, dated December 28, 2023, by and among the investors thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the Commission on December 29, 2023)</span></a></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/ex10-1.htm" style="-sec-extract: exhibit">Form
    of Common Stock Purchase Agreement, dated March 8, 2024, between Enveric Biosciences, Inc. and the investors set forth therein
    (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission
    on March 11, 2024)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315224017748/ex10-1.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Agreement, dated May 3, 2024, between Enveric Biosciences, Inc. and the investors set forth therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the Commission on May 3, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/890821/000149315223010431/ex21-1.htm" style="-sec-extract: exhibit">Subsidiaries (incorporated by reference to Exhibit 21.1 of the Company&#8217;s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 31, 2023)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white; padding-right: 0.8pt; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Dickinson Wright PLLC (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of independent registered public accountant &#8211; Marcum LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white; padding-right: 0.8pt; text-align: justify"><a href="#poa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (contained in the signature page of this registration statement)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0.8pt; text-align: justify"><a href="ex107.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because
    the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    contract or compensatory plan or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes to</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered
in such names as required by the underwriters to permit prompt delivery to each purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation
of Registration Fee&#8221; table in the effective registration statement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
For the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A (&#167;230.430A of this chapter), shall be deemed to be part of and included in the registration statement
as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such date of first use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
That for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
That:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant
    to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
    it was declared effective.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
    prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
    securities at that time shall be deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Naples, Florida, on the day of September 4, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
    BIOSCIENCES INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph. D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="poa_001"></span>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the undersigned officers and directors of Enveric Biosciences Inc., hereby severally constitute and appoint Kevin Coveney and Joseph
Tucker, Ph.D., and each of them singly (with full power to each of them to act alone), to sign any and all amendments (including post-effective
amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing
pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to
all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents
or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
held on the dates indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Kevin Coveney</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    George Kegler</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Frank Pasqualone</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Pasqualone</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Webb</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Webb</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    (Chairman)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Marcus Schabacker</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus
    Schabacker, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Sheila DeWitt</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheila
    DeWitt, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    4,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Lpq2CtI3LVrEKlJEfI12lWCbLZv4dyRvaWwRl4VlmflmhAhFTgtdI8NhVhaww6atlUMo8YyM5oTekS1XKfhb4kVbx8q47v2BGXkGPTMexMnRC531ri1WKcjJMJHDeAQySZMRTNci+OoZmbOu0DitalCmgi1Tyxqd4lefsFNPMtS8uqo9stVkUogGspffEMsohg3d1YP4aqEoMhGE3QQiZ7q13jV/OjRfEuY1Nr7O9vR/gw//pkqA -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; text-align: left; width: 50%"><IMG SRC="ex5-1_003.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1850
    North Central Ave., Suite 1400</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phoenix,
    AZ 85004</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    (602) 285-5000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
    (844) 670-6009</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">http://www.dickinsonwright.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
4,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Naples,
FL 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), in connection with the
issuance of this opinion that relates to the Registration Statement on Form S-1 (the &ldquo;<B>Registration Statement</B>&rdquo;), filed
by the Company with the Securities and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;) under the Securities Act of 1933, as amended (the
&ldquo;<B>Securities Act</B>&rdquo;). The Registration Statement covers the resale, by the investor listed therein, from time to time
pursuant to Rule 415 of the Securities Act as set forth in the Registration Statement, of 4,900,000 shares (the &ldquo;<B>Shares</B>&rdquo;)
of common stock, par value $0.01 per share, of the Company (&ldquo;<B>Common Stock</B>&rdquo;) that have been or may be issued to Lincoln
Park Capital Fund, LLC (the &ldquo;<B>Investor</B>&rdquo;) pursuant to the Purchase Agreement dated as of November 3, 2023 (the &ldquo;<B>Purchase
Agreement</B>&rdquo;), by and between the Company and the Investor. The Shares may be issued to the Selling Stockholder from time to
time hereafter pursuant to the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is being delivered in accordance with the requirements of Item 601(b)(5)(i) of Regulation S-K under the Securities Act, and no
opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the preparation of this opinion, we have examined such documents and considered such questions of law as we have deemed
necessary or appropriate. We have assumed the authenticity of all documents submitted to us as originals, the conformity to originals
of all documents submitted to us as copies thereof and the genuineness of all signatures. As to questions of fact material to our opinions,
we have relied upon the certificates of certain officers of the Company without independent investigation or verification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_004.jpg" ALT="" STYLE="height: 80px; width: 700px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dickinson
Wright PLLC</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
4,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing, we are of the opinion that the Shares have been duly authorized by all requisite corporate action on the part of the
Company under the Delaware General Corporation Law and, when the Shares are delivered and paid for in accordance with the terms of the
Purchase Agreement and when evidence of the issuance thereof is duly recorded in the Company&rsquo;s books and records, the Shares will
be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any
other matters relating to the Company, the Shares, the Purchase Agreement or any other agreements or transactions that may be related
thereto or contemplated thereby. We are expressing no opinion as to any obligations that parties other than the Company may have under
or in respect of the Shares or as to the effect that their performance of such obligations may have upon any of the matters referred
to above. No opinion may be implied or inferred beyond the opinion expressly stated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is limited in all respects to matters arising under the Delaware General Corporation Law. Our review of matters arising under
the Delaware General Corporation Law has been limited to a review of the text of the Delaware General Corporation Law as set forth at
8 Del C. chapter 1, which is stated to include all acts effective as of August 12, 2024, in each case without regard to any legislative
history or judicial decisions or any rules, regulations, guidelines, releases or interpretations thereof or any other review of the laws
of the State of Delaware. We assume that such publication accurately sets forth the provisions of the Delaware General Corporation Law
as in effect on the date hereof. We disclaim any obligation to revise or supplement the opinion rendered herein should the above-referenced
laws be changed by legislative or regulatory action, judicial decision or otherwise or any fact or circumstance changes that may hereafter
be brought to our attention whether or not such occurrence would affect or modify the opinion expressed herein. We express no opinion
with respect to the law of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement filed with the SEC on the date hereof. In giving
such consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations thereunder. It is understood that this opinion is to be used only in connection with the offer and sale
of the Shares being registered while the Registration Statement is effective under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex5-1_005.jpg" ALT=""></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dickinson
    Wright PLLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex5-1_004.jpg" ALT="" STYLE="height: 80px; width: 700px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in this Registration Statement of Enveric Biosciences, Inc. on Form S-1 of our report dated
March 25, 2024, which includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, with respect
to our audits of the consolidated financial statements of Enveric Biosciences, Inc. as of and for the years ended December 31, 2023 and
2022 appearing in the Annual Report on Form 10-K of Enveric Biosciences, Inc. for the year ended December 31, 2023. We also consent to
the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
Hanover, New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
4, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ex107.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 29.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
S-1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Form
Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enveric
Biosciences, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
1: Securities to Be Registered and Carry Forward Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Security<BR> Type</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Security<BR> Class Title</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fee<BR> Calculation<BR> or Carry<BR> Forward<BR> Rule</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount<BR> to<BR> Be<BR> Registered (1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Proposed<BR> Maximum<BR> Offering<BR> Price Per<BR> Share (2)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Proposed<BR> Maximum<BR> Aggregate<BR> Offering<BR> Price (2)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fee Rate</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount of<BR> Registration<BR> Fee (2)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="27" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Securities to Be Registered</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-align: left">Fees to Be Paid</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">Equity</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">Shares of Common Stock, $0.01 par value per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">Other</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">4,900,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right"> 0.50 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right"> 2,450,000 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">0.00014760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right"> 361.62 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right">Total Offering Amounts</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 2,450,000 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 361.62 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right">Total Fees Previously Paid</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right">Total Fee Offsets</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font-weight: bold; text-align: right">Net Fee Due</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"> 361.62 </TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    shares of common stock that are issuable at the option of the registrant pursuant to a purchase agreement with the selling stockholder.
    The shares will be offered for resale by the selling stockholder. Pursuant to Rule 416(a), there are also being registered an indeterminable
    number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with Rule 457(c), based on the average of the high ($0.52) and low ($0.48) prices of the Common Stock on
    the Nasdaq Capital Market on August 30, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
3: Combined Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> Security Class Title </TD><TD STYLE="padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
                                            of Securities</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&thinsp;Previously
                                            Registered(1)</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&thinsp;Maximum
                                            Aggregate Offering&thinsp;</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
                                            of Securities Previously</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&thinsp;Form&thinsp;</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type</B></FONT> </P></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"> File Number </TD><TD STYLE="padding-bottom: 1pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&thinsp;Initial
                                            Effective&thinsp;</B></FONT> </P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 13%"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 13%"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 13%"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> &nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 12%"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 12%"> &nbsp; </TD><TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 12%"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> Equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> Equity </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 1,279,880 (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> </TD><TD STYLE="text-align: center"> $2,431,772 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> S-1 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 333-275380 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 12/5/2023 </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.5in; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    registration fee is payable in connection with the aggregate of 1,279,880 shares of Common Stock previously registered under the
    Registration Statement on Form S-1 filed with the SEC on November 8, 2023 and amended on December 1, 2023, which was declared effective
    by the SEC on December 5, 2023 (SEC File No. 333-275380) (the &ldquo;Prior Registration Statement&rdquo;) because such securities
    are being transferred from the Prior Registration pursuant to Rule 429(b) under the Securities Act. See &ldquo;Rule 429 Statement&rdquo;
    in this registration statement.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !C 2P# 2(  A$! Q$!_\0
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>H]?06)WCZGJ@ZTZBBN<[ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_003.jpg
<TEXT>
begin 644 ex5-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  H ,P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*J:LEY
M)IMRMA/';7FP^5+-&9$5NV5!&1^-?*O[-?QT^,O[27@#6?$VGS>"-$ET[5[C
M25L;C3[N596A"Y<R"<%0Q;LIQB@#ZUHKYM^%7[56M7'QNF^#?Q5\+6_A'QX]
MNUYI=WIETUQINL0@$EH&90RL K':W/RMG!&#Z)H/[1G@G7+'QU?O?3:3IW@F
M[DL=<O-4A-O#;31J&==Q^]@,IXZ[AC.: /3J*\RT_P"/.G:E#I%VGA?Q9%I6
MJSPP6VI3:0RP_O658G<9WHC%E^9D &><51'[3W@PGQ7'MU8W?AO4H]'NK-;!
MVN)[UP&2"WC&3,Y4AL+G"G)P* /6Z*\_D^->AV_Q&T'P-<6>JVWB+6K&34;:
MWELR%$$9 D9W!PNTLH(_VA4_@GXU>$/B'X@\5Z#H6JI=Z[X7NWL]4TPC9<0N
MO1@AY9&[..">,YH [FBO+5_:.\(?\(/:^*9#J,%G>:N=!L[6:S9;JZOA*T/D
MQQ]SO1QDD#Y2<XJ_J7QS\.:!X836=<AU/03-J/\ 9-MINH63+>W=V?N10PKN
M,I?JI7((R<@ X /0Z*\QM?VA/#4?C;2?">MVFK^$]:U@-_9<>NV1@BOV49:.
M*4%D,@'.PL&]JU_"'QH\(>.O%WBOPKH^KQW'B/PQ<?9]3TMALGB)4,'"G[R'
M< &'&>.M ';U7OK^VTNSGO+VXAM+2!#)+<3N$CC4<EF8\ #U->5>)?C!J'B#
MX0>+?%'@""./5]"DNH$M?$=L\,4]Q;L5D@.&!&64H&!ZXZU\Q^"/&4_[57P:
MD^-?Q@OK5?AWX=M9I5\!Z2[BUO+Z$G<UXI^:0[MBQP$D$L"<YQ0!]+6/[3&D
M^-+J2W^'7A_6OB(L;&-M4TN%8-+5AU'VR9DC?'_3+?7:Z1J'C;4%5[[1='T4
M'_EF-0DNW_$B)!G\3]:\J^!/[36B_$O]EJ?XB1VUKX5.BV=RFIZ6D?[O3)[9
M26BV';Q@*0#C(8=*?X3_ &C=2\-_#WX=ZC\3-*GA\5>.-OV#2?#VGR2*DC1F
M5("6?(D\L;CN( (8=J /?8]_EKYFW?CG;TI]>4Q_M,^!YOA7XC\?QW-\VB>'
M)IK?6(392+=V,L) E22$@,&7()]CD9K1UCX\^%M%TSPO/,;^74?$\7G:1HEO
M:-)J%TNT.6$(Y4*I!9F(5<\D4 >BT5PVA_%BWUK5]1TN3PYXCTJ^L[3[;Y>H
M:<46>/.,12!BCMG^'=D9'%86C_M+>#M>^"M]\5;)=5E\'V2W$DL_V!Q-Y<#L
MDSB(_,55D<'_ '3B@#U:BO(?$G[3OACPMX)A\8WFD^)&\+OI46LR:K#I3O##
M;2#<A<YR&VD-M ) (SBNO\"_$JS\>1SR6^E:QI,4<4,Z2:O9&V6>.4,4:,DD
M-PO(ZC(SUH Z^BF^8NXC<,CDC/2D\Q/++[UV 9+9X% #Z*9'*DT8>-U=&Z,I
MR#3Z *NJ7]OI>FW5Y=2K#;01M))(W15 R37P=_P3A^+_ (.^'WP?\6:9XHUV
MW\-ZC)XIOKU+750UO(\$@C*2*' W X/3/2OOJD:-'92R*Q7D$CI0!\>GPI>?
MM*?MG>"/B9I&FWUCX \ Z;/%'K5];/;?VO=RAP$MT<!VB0-DR8"D@@9S4,_[
M)?BGX@> ?VB/">M;?#G_  G/BF37]%OQ,L\>T>48A,B'(!:+YE]&[XQ7V510
M!Y/X,\8?$X:9HNF:_P##F&UU57AM[[4+36()+ 1@@23QYQ*?E!(C*9R0">]>
M!V/[,WQ-T7XT?$CXI^&FM])\4RZ^]_HMGJ5V)M.U;3W@BBEMYT7)MY6,0*RJ
M-PS@Y'%?:E% 'SNW@_QQXF_:8^'GQ$O_  G_ &/ING>&[[2M2@.HPS/;W$\D
M;KLVG]X@\L_, .HXKE[?]E/5_$W]O^)TED^'GQ2M/$6HZEH'BBQ>.8R6L\F]
M(+M%.)H6 PT3].Q]?K"B@#Y>T_X+Z_J7[.NE>#/B1X#T_P 8W5[JE[=ZU::/
MJ @^S227$TT=S:.Q4@@NI'S!EW=\$5RC?LQ_%)? OPXU8ZS_ &WXM^'_ (HN
M=6T?2/$&HF9I]+D^1+.XNE4@SK&!B7! R1TYK[,HH ^=OBC\,_%/[17B/X;K
MJWA__A#=#\+:Y#XBO)[J[BGNIIH0?+MX!$6 4L?F=B/E& #GCGY_V6+_ ,;:
MAXN\02^=\/\ XA0>);K5O#'B[39(Y9EMY$C BG53^]B8H0\+]CP17U310!\*
M>+O GC;4/"?PQ^"_C$V5MKOCGQEJ&M>)O[#E;R)=/MYFNI?+)(*K(QA&T\C=
MBLOX:? ?Q-X9_:H\9_":&P,7P;;6;;X@^8=WED]8K%0?E*FX4,R\\6Z^M?4O
MC;PVLW[1GPRU^5=R6^FZO8Q<?=DD6!\_]\PM7K5 'P!XZ^ _BCPQ^UIJG@/0
M+5C\*/B]+#KFM[5/EV<EG();N,<8'G?*I!QD2XYVU] ?M,_"?Q+\1O%GPAG\
M/6LRZ?X<UYM1U"ZL[R.VGMX?(>(&'>"&;+YQCH/>O?Z* /C_ %7X&_$S3_V?
M?BO\(QI-AXA_MB*\;1O%<5U'#/J3W#%B;]&P1.I.#(N58 <+TK?USX-^/]*\
M<_"?XG^'=.L[_6_#?AX^'=9\+7UX(C- ZIN>WG&4$BNF?F ## R*^H:* /"_
M">F?$W5/C=XE\1ZM;7^E> I-!C@T_P /W.HQ2M_:.X^8X5"0%*8 RV,\XKQC
MP7^R5XFTW]B_Q#X(U/2;Z/Q_<6NIP6]I;^(YELG>XFE>)BJRB(*%D7<"O)!X
M.:^VZ* /G;XC?"GQ9XH_8?E^&]EI<9\72^%K;1/LKW,:QK.D4<;-YF=NW*$@
M]^*Z3QA\/]>\2_#WX9Z7'8K#=Z3J6GRZE#)(C".&*%DE[[9!DCY>XKV6B@#Q
MWPG\/M6^'_Q.62QT^ZU3PTGAVQT:*[FO$:0/%-*79U8Y/R.O(ZXQVKE?"WP]
M\=Z5\/?AYI=WHJW(\-7+2:KI$U_&4U-'$P4H^2"8F:.3:^ W3.17T910!S_@
MRQBL;"[,.@_\(\L]T\QM=Z$N2%!D(0E5)QT'IGO70444 %%%% !1110 4444
M %%%% !1110 4444 5+W38;^6UDE!$EM+YL;*<$'!!'T()!JW110 4444 %%
5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex5-1_004.jpg
<TEXT>
begin 644 ex5-1_004.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !R ^@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***Y'Q1X)U77]3^U6?C36M!AV!?LE@EL8\C^+]Y
M"S9/UH ZZBO.O^%7^(/^BG>)_P#OU8__ "/1_P *O\0?]%.\3_\ ?JQ_^1Z
M/1:*\Z_X5?X@_P"BG>)_^_5C_P#(]'_"K_$'_13O$_\ WZL?_D>@#T6BO.O^
M%7^(/^BG>)_^_5C_ /(]'_"K_$'_ $4[Q/\ ]^K'_P"1Z /1:*\Z_P"%7^(/
M^BG>)_\ OU8__(]'_"K_ !!_T4[Q/_WZL?\ Y'H ]%HKSK_A5_B#_HIWB?\
M[]6/_P CT?\ "K_$'_13O$__ 'ZL?_D>@#T6BO.O^%7^(/\ HIWB?_OU8_\
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M_P"1Z /1:*\Z_P"%7^(/^BG>)_\ OU8__(]'_"K_ !!_T4[Q/_WZL?\ Y'H
M]%HKSK_A5_B#_HIWB?\ []6/_P CT?\ "K_$'_13O$__ 'ZL?_D>@#T6BO.O
M^%7^(/\ HIWB?_OU8_\ R/1_PJ_Q!_T4[Q/_ -^K'_Y'H ]%HKSK_A5_B#_H
MIWB?_OU8_P#R/1_PJ_Q!_P!%.\3_ /?JQ_\ D>@#T6BO.O\ A5_B#_HIWB?_
M +]6/_R/1_PJ_P 0?]%.\3_]^K'_ .1Z /1:*\Z_X5?X@_Z*=XG_ ._5C_\
M(]'_  J_Q!_T4[Q/_P!^K'_Y'H ]%HKSK_A5_B#_ **=XG_[]6/_ ,CT?\*O
M\0?]%.\3_P#?JQ_^1Z /1:*\Z_X5?X@_Z*=XG_[]6/\ \CT?\*O\0?\ 13O$
M_P#WZL?_ )'H ]%HKSK_ (5?X@_Z*=XG_P"_5C_\CT?\*O\ $'_13O$__?JQ
M_P#D>@#T6BO.O^%7^(/^BG>)_P#OU8__ "/1_P *O\0?]%.\3_\ ?JQ_^1Z
M/1:*\Z_X5?X@_P"BG>)_^_5C_P#(]'_"K_$'_13O$_\ WZL?_D>@#T6BO.O^
M%7^(/^BG>)_^_5C_ /(]'_"K_$'_ $4[Q/\ ]^K'_P"1Z /1:*\Z_P"%7^(/
M^BG>)_\ OU8__(]'_"K_ !!_T4[Q/_WZL?\ Y'H ]%HKSK_A5_B#_HIWB?\
M[]6/_P CT?\ "K_$'_13O$__ 'ZL?_D>@#T6BO.O^%7^(/\ HIWB?_OU8_\
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M'_Y'H ]%HKSK_A5_B#_HIWB?_OU8_P#R/71>$?"^H>&_M/V[Q/JGB/S2-O\
M:2P+Y6/[OE1IU]\T ='1110 4444 %%%% !1110 4444 %%%% !1110 445Y
MU\=?C)!\$O!:ZXVD77B"[EN8[:WTNQ8":8DY<KGLB!F/LM 'HM%>*>.?VD#H
M?BCPMH?AKPW)XIN-?T.X\0PR"]CMHQ:Q",D L#EV$@P.!ZD5?\&_M"6OQ&DL
MH_#>BW-U)J'A@>([);N18/,S)Y8@;(.UMW\7(^M 'KE%?/MK^U/>Z;JGBJS\
M2^"9M..@K:P,^FZA'>_:+^X8+#8IA5_>D%6/90P)Q6W<?M!:AX;O[O3/%W@R
MZ\/:HVD76L::BWD=Q!?+;IOE@$JXV2J"N01C#9!- 'L]%>->"_VF-'\<>#/!
M>O66F744GB#4X](N=/G8+/IERREF24=R,#IU!!%:7@WX^:;XQ^,7B?P##IT]
MM)H\6^'4I)%,5\RE1.D8ZYC+H#_O>U 'J=%%>?\ Q'^*S>#=9TGP[HVAW/BC
MQ9JB23VVEVTJ0JD$9 >:65_E1 64=R2< &@#T"BO)?B-\<K_ .%?PC'BW7O"
M%U_;;3"W3P[974<TLCDDD+(!M($:N_3HN*O6GQSTS4OB)X-\+V5G)=1^)M%F
MUJWU".53&D:;/E([D[^H]* /3**\3^)W[28\ :]KFB6OAJ?6-2T^?2+:%!=)
M"EQ)?RM&@W$':%*Y)/K6KJWQFU?P[I^A6.I>$)#XUUVYE@T_P_8W\<P9(UW/
M,\^ J1JO).,\@ $F@#U>BO!]>_:BD\,Z;K%IJ?@^\M/&&FW]A8MHK74?ES"\
MD\N">.<#!B+!@3@$%2"*I^*/VNK?P/X1U+5-<\(W\&H:/X@MM!U/3[6XCG\K
MSH_-$\;K_K$$9W$8#<'CB@#Z$HKQ/QQ^U#I'A#5A;6^ES:Q:20Z9<0WMM,HC
ME2]G\E&7(Z+]X^M;'C#X_:;X0^,WA?P!-IMS<-K"$S:K&P$%C(W$$<F>2TK
MA<>E 'JE%%<E\3/B18?##P['J5Y;7.H7%U<QV-CIUD@:>\N9#A(D!( )P222
M  "3TH ZVBO']1^.&N>%]+LU\1^!KBP\1:M>K8Z+HEIJ$-S)>N5+,2XPL:H
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M7BN8M?VE)UL=$\1:GX*U+2O NM745K::Y--&TB>:VV&6>W'S1QN2,-DD;AN
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M"G+$L. ./6@#Z%HKQKQQ^T?;_#G6K_1M=\/W4.K?V=!>:1;PS))_;$SG8]M
M?^>B.0",?=^;I5KXF?M!V?PMUWP-I.JZ/<2W7B&54O#!*K+I49VJ9I3_ !()
M'5,CN<T >MT5YGJ'Q@NI/BM<^!]#\/-JUUIT%M=:G<2WL=OY,4S,%:-&^:7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_005.jpg
<TEXT>
begin 644 ex5-1_005.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y 3T# 2(  A$! Q$!_\0
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M*]WKKIU/-[CXA7_QG_9/^*NL:\(+*W9]6M+1;<[2EO$=L8<D_?R"">_%>7?
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M;>F.U.HH **** "JZZ=:+?M?"UA%ZT8B:Y$8\PH#D*6QG&><58HIW *2EHI
M%%%% 'S?X3UZR\8?MN^)[G1Y4O+31?"T6G7MS"X>,3FX+;,CC(R01ZJ?2OI"
ML7P[X*T#PC+J,NBZ/9:5)J-PUU>/:0+&9Y6.2[D#DY)_,UM5V8JM&M*/(K))
M+[D<]&FZ:?,]6VPHHHKC.@**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>envb-20240830.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaKPSbP9z5Z8OekhvWB0bQnajyEh9b1JTiREkfcWIZ8B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ENVB="http://enveric.com/20240830" elementFormDefault="qualified" targetNamespace="http://enveric.com/20240830">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240830_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240830_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240830_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>envb-20240830_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20240830.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentCreationDate" xlink:label="loc_deiDocumentCreationDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentCreationDate_30" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="59" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>envb-20240830_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentCreationDate" xlink:label="dei_DocumentCreationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentCreationDate" xlink:to="dei_DocumentCreationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentCreationDate_lbl" xml:lang="en-US">Document Creation Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>envb-20240830_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.23b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20240830.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentCreationDate" xlink:label="loc_deiDocumentCreationDate" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentCreationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140464125439360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4851
Tamiami Trail N<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentCreationDate', window );">Document Creation Date</a></td>
<td class="text">Sep.  04,  2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4851
Tamiami Trail N<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Joseph
Tucker<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentCreationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentCreationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !6E219JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( %:5)%EED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !6E219)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !6E21999!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="forms-1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>envb-20240830.xsd</File>
    <File>envb-20240830_def.xml</File>
    <File>envb-20240830_lab.xml</File>
    <File>envb-20240830_pre.xml</File>
    <File doctype="S-1" isOnlyDei="true" isUsgaap="true" original="forms-1.htm">forms-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "forms-1.htm": {
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20240830",
   "dts": {
    "schema": {
     "local": [
      "envb-20240830.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "envb-20240830_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20240830_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20240830_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "forms-1.htm"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 66,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://enveric.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-08-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "forms-1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001493152-24-035018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-035018-xbrl.zip
M4$L#!!0    ( %:5)%D)"K:.. ,  -8,   1    96YV8BTR,#(T,#@S,"YX
M<V2U5MMRVC 0?>],_T'UNVTN30H$DFE"TJ$EET)NDY>.;*]!Q4BN) /IUU?R
MC8N! FUXDG?/.;NK74DTSV;C $V "\)HRRA;)0,!=9E'Z*!E//3-S_V+3L=
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M69VIU*)M84C4O.8&9=+];7 6P+U*'.F%.D]K(VB??<&4P4#$:QG)<D$K4_/
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MK26T:,54?:R6-Z?S-V;\+0X: I=%5/+7?09AD9)]'-:-^=^=W1J1X9,FZ']
MAX8]8 J*P=>-0--.U-3R#U!+ P04    " !6E219IJ*"L 4*   P=P  %0
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MS",8[:1;"K2$?P@Y),4'5SMHPWU?YL&X8A&BNM8?[")831M./XP9)-[5UMK
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M9120]-HS81$!XZ01@<H0I&+"8G.9YUO"7P6/(R000J!Y "1+'R-.D,E>J,K
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MR.4(*HS!5\$[@SS?7AA0 >,F0T=$1.@-L G=<%"12(6^0V4P:D0'.C_+]UD
MR>KCRQ=R1[A\[F!!=L5'L:.'CC., ;&^S]X&5\<\F>L-C +"U[J%3O5RU"P
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MI<X4+?NPV\LJ!:U?=B-W,'?.6<O+.7FEE#V$7L!1;TTOY^QH151\SQ+3H;R
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M:\[B,G_%-&I]2$+#<JEW33 \]F,4@8E!IJ4%#6>HX(=7P9 G WHP!NR) 1.
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MPS=3]4VN("OX&W?<K^#!W]3S?U!+ P04    " !6E219H._A_-O5  !.8P<
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M1^5@#=TL3UPYCBYE2DAX.K!DI4^G[C@8C;%Z#T1/CG7FR@<81)=Q>(GD0%>
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M01#@7N=5.+PE0 :IDJ +5HY]%6D .RD2&"_+7N>.F :F.;D&>86!H;&#D$A
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M077-1X1:'"AR5JVP>))PYC8'0,&POKB=!'<C!F-'D7UIR.A<#H"P,S!:-X%
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MD!Y7>K'GQMS4S*!/^F)FZFE!+DA4<!3D4XD+VIR,67UG!RLFG25\/M"-P13
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M!YK7GW7'\H,OU9\L'2C B-L,YHRT@ZZ<M-)$O-Z+H)J))S).1B(*_A*ZL?5
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M<>U8T3>%8T,KJJCJ0$Q\-Q672&1P%F:1!)U,^49&27R5C0N4"^##?9T.1>4
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M>A[!8JN2+7:P>*P%HG.JR/7EQ[,C!YVQ.!:"QIPB=@6Y0QHZ;NAX93JVTH9
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M$;!J&XN70Q$P($/<#U5E#@+AYU.,M- /_"1]%*G.8)K#Q0/*XHCBG.U5C>5
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MVUMN%V"F2A(0^N;PC;L1O#1WM[=;WO;N[K(CI^T'/+_.P]@/M"FV_8 [MQ'
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M"YQ7R--Z7NCGIMJJW<*$Y53A6)<,K]0U^8*FIV7)]%V<AU_FLKJR=#&3_9:
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MAZ<GIH$U(<.MJ3(<7]1WDP=*IL-NQ+IB12'N/#,!KZ*8KWI*I?/\Z$QJP2V
M; DW#GP^A3U_OZK_&.C?\^6?O%RI!,9$(;(K+<K\%J5=GJ15Z=AB->#WSZ.:
M&,.RIGE4I2%9:A[5JB914>NWP3"JZ]P<.F6M>.A4A9*:VE1X5V5V+38%:M:\
M)^.AND&^ZCRM:3MQJDG&KD<XES"RQ:.:[O<D*PMHPN["EV5&_2R\"&>A<S_M
MD7-X J?9/%;?V,OUW^207>.59)86?*E;98WL3Y%C$BN   P>>6)A>9R7ZD24
M \ZU-70:AG@1/PJ1RA9C<_ITH:*^S17U3L&0_>0FGOLG2!F<$ O>8E]8-U22
M=7#8.=AS@>*]WCX7VH)YK^C/S8E"A8HLA38HL$_5FK0[ #:"+NAX$K+0#UB(
MS"ESS7(_F,WXQ&<!KYF'-Q<5M:6R#DNE"Y8*@=PEQ9+J8.8\WFI?:49U4UGQ
M3 FNS'0/C.[C::_QE5 '"97WR5)M82BA3Y1*,PK\2A$A-9O4Z"5'RV*'[N?L
MSM>CNO/UNSM?NW7GZU9UOFZG0EAUV^Q_FLV6[II]?WY[=G-Q?7=Q]0EAV6[/
MSS[?7-Q=G+\8,-LV(.>MI6SY)[\T[)-1+D:L7+,AT >?9@4_Q&G:_A!A14@=
MJ_@8&;C:76G8[V3<TJ= (X417/DL] '20AT\F8P2B=LR6T],Q#?CI9$]CK*&
M_0%3#!*M)!4FU0Y^ #$W> :IM&>1QM,A.CF<"+L19#EX]ED.H8%KN0@5WA$&
M'_=DW]>L#\GVKWT9>)2/[8T#]PD\#?F =_2C^JAC"Y=1@%PF"2,,(Y_-B3Q\
MRNDB-['$UP>_YZ?); MH>@,P;BIF:] J<8P7^'H=[*G0;I&R01PH'R&__#6V
MA;=/&JV#T5(K4+;:X 8!*]-P%GE$ZVW:;Q\VVIM^.&L1J><AV#E^W\(&.#<#
MKP,EJ&>W>/1(*7ZJ4,?DO'#@4!O<9/"/_])L-%MYP,[)N;O5S!_DQE-STRB.
M\E=:Q4]*L=0+W/"+W7\0_2\*%W#$S2+"LV5[TVDU2'Q*V(%/^#]5C8=R$TI1
MF;R+Q.A%=-#CRK^)VPK_>E>F9.JWVQVG>=PNN9P%=#N%%&91=$M\%7'?3R1V
M9=X2&8TXJ7)/:$DJ$$00!7]F&+8%<8D@98_"'L&^41S'M;EF#^F28XKUXSGD
M"B_YRV&[<71DG*5UW.TZA\VC:4>7(\^7Z7VB#NAT@7=W#AI'Q^8]0E2*HXEK
M.-_K\R,Q2B74OLU-4@NN=A-)LB1)G:.VT^K.=81,$[Y;QLA0X\*34WU-LA U
MI3Q$1W7F/=*K6X=.LWVHW@.K>?2C+ G&%CY0WBWX/EVTAGV.2EJ&H/*-ER46
ML[<BU@LGH@=DK4C 4D0#)'I"SAL\N,$ @<3\>&SQ1R3(*C#: :I\^.^)1"+,
MQ8E)ZBP1D%9]#<PED(BD]O.OZA5);J4T@0Y[#VB,@DQ"JQ$%*M0G<\ 5P4X=
M'^0 -G_.QX K@<^1V2&A[? M8"79W.MHZ792BK8014*%_"(%!U(T/96Y&&"
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ML E3@!+& XBL@4_%XM%3B+ 9\'G"K'5-KB44G  $7(P0.U1[K3"F"+7"#0@
M1"2I8[F@ T9C!?6',CD'<\@KN!8KU2(1B $)347.*Y6 8);2>+EZ*P!</?-Z
MMK44L0W[WU&&&#P9R#TYT@W7)I?,@&OYTM)H195EV]<8\J*5H><AW R_;[WS
MHZ3OXV'"YR_"?F.KZUV[QP<MZPZ^#_]GW\4N:/5/SE:OZ#8#R])"%*U/[HA@
M^S]<;O6"[D0@1@]1**R]=N=DW^XTVV_ Q3_:ZD6=HG1'R^5OUIEV7<!JCT4*
MYOWV+FU'M#YH),:01^_2[??E[)W$T+&./8@%.11L"CBJ6PRL2]W7]21ZB9_2
MF(J?_)^-$,U/;_V?2;EST*OX.3.D(UCL-OK1\*T/_T[2*$[>2MOY+3ZF8=T]
M3(=!=MB5@ <CY#RBE-)J\H&H3H$ 7PUGG:[ V<62'R1'(QHX%4"6'*'I][G5
M#4TBX\^Y7U';M^L>QX5G%'O4&LB@<@C#V&VUJV>32$1'[8L6HI)N[N!,OT+2
MD4H>7(908)?+(H_(9R],.WI>E8OE5KY>/I:',QB ]UDOH>:L5#N"N9<HO70,
M(=&5A3L\W0&L6H0D.BD0+>,YFLCZBG];X+/9Z*Y KDM/(T:09AK\%H6SI>=L
M;\:9\*94=+I:W"'&- 9[+!2?LKGV_U)68(SP^FFDXBKV&-PB8DB3.KAN]/94
M#?UP2RQ8 <0_>P%EP'VB$%TZ)'#H?N&8W@#K1-%W$T%0Q@*4_/8'_)QX?E\%
M9)B[B!5P: H!=R.;1 &XQ*FK(!.+^V Q_ZKPEE PCI(0>MK,1^53\!"U'P@F
MH%3&F)<;3!XX VMF8> ^#;*  DWN%Z'(M2K?L4;,L^7SPI;[H^\O;L\NKVX_
MWYQ3.^+5QX\7M[?8A7A]=7M![8A7V)WX_OSCIXL/%V?<H?CAZ@;ML\\W\(GS
M6_OT[,Z^O#A]=W%)/]?83.NV1A"<D$- 8.62( 4^]/LH>[@#D?'<_=PN -X%
M)S=5]L$(8_=ICH#[7@!_XU?A/RS84-D/05K*(1Y)%K/E0P('I& *+T]HS$7^
MZE %IH@JB2./(J\(Q$_I)&\***L/HD3$CSZ#,;"8 9L<FPS3<6TAK-D(3J*!
M&ULT9T]>,3GO=$ S8!<8?R"GA>4746;)]05RBA>+4GH1(RS+>0]6>2*B1NEU
M-(SRDY^ R_DDC,21 I&6XW0X<37R0R./A9D/<[: 7J:?WVL)F3)"O3>V&/0C
M9I=1/K2T8G8'':YW0U(Q/R;09ND+3)?3G%RRX1\-$[X?N/Z0MK=,BR*D/*W
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MD$Z0WILF)$! 2!Z>N??=?]X?[YZU9\WL/7O-GOU9:Z_OS";,$5: :]KJ6NH
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M)J6CM8:+ .2EJU^'/[OG:%@Z_'I^!Y( 2?!:7_V:2D[VHPPX$'N4B6>>>4T
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M?;V"V&T%XEC^=_]V,&'^?P!02P$"% ,4    " !6E219"0JVCC@#  #6#
M$0              @ $     96YV8BTR,#(T,#@S,"YX<V102P$"% ,4
M" !6E219IJ*"L 4*   P=P  %0              @ %G P  96YV8BTR,#(T
M,#@S,%]D968N>&UL4$L! A0#%     @ 5I4D656GT$BX"P  :9$  !4
M         ( !GPT  &5N=F(M,C R-# X,S!?;&%B+GAM;%!+ 0(4 Q0    (
M %:5)%E@$![RH @  )UK   5              "  8H9  !E;G9B+3(P,C0P
M.#,P7W!R92YX;6Q02P$"% ,4    " !6E219+_EY5M8(  #*4   "0
M        @ %=(@  97@Q,#<N:'1M4$L! A0#%     @ 5I4D6:^AW=%U P
MDPX   H              ( !6BL  &5X,C,M,BYH=&U02P$"% ,4    " !6
ME219K&V!-M@+  "P1P  "0              @ 'W+@  97@U+3$N:'1M4$L!
M A0#%     @ 5I4D6:#OX?S;U0  3F,'  L              ( !]CH  &9O
M<FUS+3$N:'1M4$L! A0#%     @ 5I4D65RX.YZ7$P  W!0   \
M     ( !^A ! &9O<FUS+3%?,# Q+FIP9U!+!08     "0 ) "0"  "^) $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>forms-1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20240830.xsd" xlink:type="simple"/>
    <context id="AsOf2024-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <context id="From2024-08-302024-08-30_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-30</startDate>
            <endDate>2024-08-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-08-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-08-30" id="Fact000004">0000890821</dei:EntityCentralIndexKey>
    <dei:DocumentCreationDate contextRef="AsOf2024-08-30" id="Fact000009">2024-09-04</dei:DocumentCreationDate>
    <dei:DocumentType contextRef="AsOf2024-08-30" id="Fact000010">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2024-08-30" id="Fact000011">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-08-30" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-08-30" id="Fact000013">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-08-30" id="Fact000014">4851 Tamiami Trail N</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-08-30" id="Fact000015">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-08-30" id="Fact000016">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-08-30" id="Fact000017">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-08-30" id="Fact000018">34103</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000019">Joseph Tucker</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000020">Enveric Biosciences, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000021">4851 Tamiami Trail N</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000022">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000023">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000024">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000025">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000026">239</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="From2024-08-302024-08-30_dei_BusinessContactMember"
      id="Fact000027">302-1707</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="AsOf2024-08-30" id="Fact000028">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="AsOf2024-08-30" id="Fact000029">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-08-30" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
